cox proportional hazards models
young woman ; family

case-control study design
EH

Clinical comparisons
exercise ; cardiovascular system
HF

reporting ; Cell
Doxorubicin
doctor ; blood transfusions
study-related
recommendations
molecular mechanism
dXA
devices in heart failure
FM
Liver disease
adverse events
HF ; PNA
exercise ; cardiovascular health
Renal artery stenosis
Retrospective cohor
surgery ; heart transplant recipients
hospital mortality
NO production ; EC
tertiary referral centre
breathing ; heart beat
cohort study
heart failure ; Latin America
Retrospective cohort

HF
mortality
Patients

trial
doctors
data
Trials
Heart rate
nutrition ; heart failure
Northwest United States
heart failure
surgery
design
INTERventions
unilateral
Heart failure


clin
trans
Sci
Jehovah ; Witness ; severe anemia
exercise modality

dodson ; interest
secondary study
CHF treatments

intermediate frailty
competitive collateral growth patterns
autonomic balance
LV fibrosis
HFpEF

ST2
Heart failure ; cognitive impairment ; mortality
department of cardiology
median followup duration
HF cases

inpatient medical conditions
impact of frailty ; HF risk
Indices ; CO
cardiac transplantation
cognitive function ; quality of life
Heart rate variability ; risk stratification of cardiac patients
taxonomy
descriptive research
Sham-operated animals


policy recommendations
Compliance

Heart failure ; UK
rates ; risk factors
air pollution ; heart failure
Patients
cardiovascular disease
temporal trends ; HF
extracorporeal support
Heart failure ; disease complex
hatasis
matched cohort study
remote ischemic conditioning ; heart failure
Heart failure ; bisphosphonates
right heart failure ; pulmonary hypertension
Caspase-3 gene expression ; heart failure
diuretic use ; heart failure

genes

patients ; hypertension
american ; european HF guidelines
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure patients
Literature
etiology
HFpEF
ejection fraction ; sex
Pigs ; antiarrhythmic medication
beta blockade
CHF patients
surgical tactics ; hypothermic circulatory arrest
functional capacity
systolic dysfunction
cronbach
trial
frailty ; heart failure
median age
AT
trial ; implanted monitoring devices
few treatments
patient safety ; conditions
HR ; afterload burden
periprocedural deaths
RAS ; atherosclerosis
exercise ; heart failure
MicroRNAs in heart failure ; disease management
cox regression analysis
PSSS ; exercise training
management of heart failure ; preserved ejection
Cardiology ; bromodomain inhibition halts heart failure
heart failure hospitalization ; cardiovascular death
Mitral stenosis reversed ; medical treatment for heart failure
vasopressin ; congestive heart failure
Trastuzumab-related cardiotoxicity ; breast cancer
Medication regime ; sST2 values
physician volume ; hospital volume
sts HM
pde2 ; HF
Nights ; hospital
public health problem
postoperative normalization ; albumin level
aortic pressure curve
physician continuity ; discharge
arrhythmia
heart failure ;HF therapy
Cardiac symptoms ; congenital lesions
spironolactone ; systolic heart failure
eRK1/2 molecular scaffolds ; heart pathology
functional MS ; degenerative MR
Epidemiology ; chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox proportional hazards models
Tolvaptan ; vasopressin ; receptor antagonist
systematic review ; network meta-analys

propensity score

black patients

metric choice ; readmission metrics
eu exerts beneficial effects ; CHF
readmission metric

liMITation ; Residual confounding
quality of life assessment
median followup
heart failure ; emergency department volume
meta-analyzed mortality
cardiac ; inflammatory biomarkers
HF ; cardiovascular hospitalization
hgb level ; baseline HRQoL
preserved ejection fraction outcomes trial
biomarkers ; chronic heart failure
survival projections
cox proportional hazards models
acute kidney injury
postoperatively secondary ; multiorgan failure ; sepsis
psychometric testing ; self-Care of Heart Failure Index
Nordic walking ; heart failure
cox proportional hazard analyses
baseline ; heart failure scans
Pharmacological treatment ; acute heart failure
MS
Hemodynamic phenotype ; failing Fontan
Coronary angiography
dialysis ; device implantation
off-pump sternal sparing approach ; HeartMate II exchange
VO2max

factors ; survival
HR ; HF
ESRD
MAIN oUTCOME MEasURE
biomarkers

prognostic factors

US healthcare programmes
clinical trials
abnormal cardiac T2
trials

interventions
risk
Heart failure ; left ventricular ejection fraction
abnormal HR variability ; sudden ; non-sudden cardiac death

chronic kidney disease ;CKD
progressive disease ; resistant hypertension ; end stage kidney failure
hospital ; heart failure
skeletal muscle abnormalities ; exercise capacity ; Fontan circulation
Physician volume
systolic HF
oUTCOME ; readmissions
prognosis ; pathophysiological
medication ; resting hemodynamics
lack of correlation ; indices

patient satisfaction ; sustainability
gross income ; expenditure ; health per capita
mice ; aac ; cardiac hypertrophy
AHA ; ESC advocate
data
clinician expertise
treatment ; end stage heart failure
HF
patients ; heart failure
acute heart failure trials
toxicity ; systemic blood pressure

adherence ; CPGs
enrollment



MS
endothelial function ; flow-mediated dilatation
standardized nursing terminologies
HF ; chromatin hyperacetylation
eseptal ; filling pressures
care management ; telehealth
preoperative demographics
reporting ; quality
sinus rhythm ; AF
cardiac rehabilitation
Race ; spironolactone ; severe heart failure
Myocardial infarction ; adult male Wistar rats
physicians ; HF
anemia treatment ; heart disease
race ; exercise training
Rhythm- ; rate-control strategies
ingenuity path
treatment algorithms ; post-LVAD AI
patients ; severe AI
acute heart failure
Population-based ; retrospective
QR

adverse events
median followup

deficit index ; deficits
gLS ; CV events
MS

anaerobic threshold ; heart failure
renin-angiotensin-aldosterone system inhibitors ; heart failure
CHF ; unilateral renal DNx
Mitral regurgitation ; HF
recruitment ; intervention compliance
Heart block ; pulmonary artery snared ; biVP
resistin ; inflammation ; metabolism
CAD ; systolic HF
diuretic ; outcomes
cardiovascular events
Bioinformatic analysis ; microarray data ; heart failure
AF patients ; echocardiographic examination

congenital heart lesions
health-related
PVF ; recovery ; PB characteristics
economic savings
Nurses ; patients
sST2 concentrations ; BB therapy
MS ; surgical indication
ICU mortality
Cardiac function ; pressure-volume conductance catheter system
cRT ; dialysis-dependent patients
beta-blockers ; adherence
CHF patients

HF
ischemic cardiomyopathy ; male sex ; mortality
unfolded protein response regulates cardiac sodium current ; systolic human heart failure
diastolic dysfunction ; peripheral artery disease
western blot analysis ; immunohistochemistry ; electron microscopy
angiotensin receptor neprilysin inhibitor ; heart failure
idiopathic dilated cardiomyopathy
hypertensive LV dysfunction ; mild MR ; MS
Hypoalbuminemia
prognosis ; C'd HF
MS
exercise training ;ET ; endothelial function
FFM ; FM ; body weight ; CC
coronary disease ; heart failure
safety ; neurological ; cardiovascular events
periprocedural ; dialysis patients
signalling pathways ; adaptive ; maladaptive cardiac remodelling
heart transplant
AF ; precipitating factor ; clinical deterioration of HFPEF
hHF ; dPP-4 inhibitors
bundle branch block electrical activation sequence
Southeastern Minnesota ; HF
Frailty ; risk of HF
proteome of HDL particles ; shotgun LC-MS/MS
multihospital study ; heart failure guidelines
proteins ; TAC
Cardiac cachexia ;CC ; body composition
length of stay
social support ; barriers ; exercise
heart rate variation

Mediterranean ; DASh diet scores
diabetes ; EO-CFUs
risk stratification ; death ; hospitalization ; heart failure clinic outpatients
Cardiac-resynchronization therapy ; heart failure
hospital readmission reduction program ; congestive heart failure
HFrEF ; HFpEF patients
physician continuity ; death ; urgent readmission ; discharge ; heart failure
nitroxyl ;hno ; acute treatment of heart failure
LVET ; admission ; follow-up measurement
odds ratios
blacks ; peak VO2
pharmaceut
aerobic exercise

trastuzumab-related CHF

Peak VO2
ranked hospitals


haemodynamic ; neuronal stressors
Heart failure risk ; rheumatoid arthritis ; TNF antagonist
HF hospital admissions ; transplant ; ventricular assist device
Coronary artery disease ;CAD ; systolic heart failure ;HF
preoperative hypoalbuminemia ; lVAD surgery
holosystolic murmur ; third heart sound
psoriasis ; atherosclerosis ; incident cardiovascular events
CV death ; non-fatal stroke ; hospitalisation ; heart failure
Renal artery stenosis ;RAS ; peripheral arterial disease
clinical studies ; elevated resistin levels
subclinical atherosclerosis ; general linear models
Wilcoxon matched-pairs signed-rank tests
incidence ; ESRD ; outpatients ; HF
left ventricular assist device ; right ventricular support
baseline ECGs
right ventricular function ; body composition
deficit index ; biological phenotype
exercise intolerance ; chronic heart failure
heart transplantation ; left ventricular assist device
ECCT ; advanced heart failure therapy
atrial fibrillation ;AF
cachexia ; right ventricle ; heart failure
AVd ; VVD variations ; free wall RS
preoperative clinical ; laboratory variables ; mortality
Unilateral renal denervation ; autonomic balance ; conscious rabbits ; chronic heart failure
regulatory subunit ;RI
Pediatric heart failure ;HF ; morbidity ; mortality
heart failure
high-risk patient ; heart failure ; reduced ejection fraction
cPET guiding exercise rehabilitation ; CHF
eplerenone ; primary composite endpoint
ecCT ; standard criteria cardiac transplant recipients
VEGF inhibition counteracted ; b on cardiac function
Heart failure ;HF ; cardiovascular hospitalization
malfunctioning HeartMate II lVADs
extubated ; blood loss
recovery
discharge ; follow-up medication list
β-blocker ;BB ; sST2
bromodomain proteins
miRNAs ; cardiac pathogen
prescribing guideline-recommended medications
iCD-HF patients
septal defects
MLHF
coronary heart disease ; stroke ; heart failure
patient ; mortality rate
bt ; DT
heart failure care
ST2
incident HF
biomarkers ; HF
hypotension
Fatal ; nonfatal outcomes
economic
derivation cohort ; CAD
Age ; renal dysfunction ; post-transplant morbidity
lVAD implantation
Cardiac hypertrophy ; energy metabolism
NP assessment ; ED patients
trastuzumab
treatment
Renal DNx ; circulating plasma NE ; CHF-INV rabbits
Heart failure disease management programs ; medical resource use
pre-HCT germline DNA
HDL-bound malondialdehyde ; HDL-induced NO production
median follow up
blood work drawn
anemia ; heart disease

survival ; hospital discharge

data ; validity
readmissions ; follow-up visits ; heart failure
Myxomas ; right atrium ; pulmonary arterial vascula
Orthotopic heart transplantation ; oHT ; end-stage heart failure
right atrial myxoma ; pulmonary embolism ; right heart failure
Nfat ; mir-25 ; transcription factor Hand2 in heart failure
resistin correlated ; decline in ejection
Framingham Heart Study criteria ; HF ; EF
coronary artery disease ;CAD
diuretics ; congestive symptoms ; heart failure
radiological signs ; HF
east ; rhythm control therapy
Cardiac ; Mammalian ;Mena ; exacerbates heart failure ; mice
lVAS support ; bridge to transplantation
apoptosis ; canine model of chronic heart failure induced ; tachycardia
pump failure ; driveline injury
cPCs ; functional capacity ;peak VO2
evidence-based
Nicorandil ; doxorubicin
concentrations of soluble ; s s2 ; heart failure
EH
ischemic ; inflammatory abdominal problems
aCP ; clinical practice guidelines grading system
MedLine ; EMBASE ; cINAHL
ED visits ; intubations ; congestive heart failure
aCR ; CMS
HF
hHF ; saxagliptin ; sitagliptin
Frailty ; risk ; heart failure ; health ; aging
Caspase ; paced myocardium
Heart t2 ; arrhythmias
anecdotal ; perceived benefit
device implantation ; CRT capability
electronic databases ; world health Organization website ; HF
therapy
degs ; osprey


Medicare ; post-acute care transfer policy
QRS
ED visits
deficit index
Diet score ; vegetables ; nuts ; whole grain intake
internal consistency ; test-retest reliability
iron use ; trial
RAS- ; β-blocker uptitration
Gastrointestinal bleeding ; ventricular assist devices
QT intervals
bottleneck stent model ; chronic myocardial ischemia ; heart failure
remote monitoring ; hospital discharge ; patients with heart failure
right ventricular contractile reserve ; pulmonary hypertension
baseline ; echocardiograms
Soluble ST2 in ambulatory patients ; heart failure
LV filling pressure ; severe systolicHF
Titin hypophosphorylation ; myocardial DD
atrial fibrillation ; pacemaker
t1 mapping ; myocardial fibrosis
medical management ; heart failure ; Canadian Cardiovascular Society guidelines
psychosocial factors ; exercise training ; heart failure ;HF
emergency cardiac catheterization
pump exchanges ; pump malfunctions ; pump thrombosis

HRQoL ; exercise training
NOc outcomes ; outcome ratings
cardiac resynchronization therapy ; dialysis-dependent patients ; heart failure
strategy
inpatient records ; patients discharged ; HF
laboratory report model
skeletal muscle mass correlated ; poorer VO2
ees ; ventricular-arterial coupling
pneumonia
autonomic nervous system activity ; QTV
diastolic failure ; cardiomyopathic restriction
Patients
mortality predictors ; iCD-HF patients
human myocardial tissue ; pKA subunits
body mass index ; CRF ; treadmill exercise testing
AF-free probability ; catheter ablation ; maintenance of sinus rhythm
paediatric cardiac transplants
ethics Rounds
high-risk patients
exercise attendance ;SD


parallel-group ; single-cohort study
renal DNx ; cardiac autonomic balance ; CHF
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure patients
anemia ; heart disease
neurohormonal stimulation ; inflammation ; endothelial dysfunction
end-stage renal disease ; outpatients ; systolic heart failure
Heart Failure ; Pathophysiology ; medical treatment guidelines
RVPO ; biVP ; RS synchrony ; CS
parasympathetic neurotransmission ; acetylcholinesterase inhibition
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure
exercise training ; chronic heart failure ; high-density lipoprotein
cardiovascular death ; HF hospitalization ; exercise training
acute autonomic nervous system modulation ; QTV ; HF
resistin ; acute anthracycline-induced cardiotoxicity
Myocardial PDE2 expression ; activity ; advanced human HF
clinical outcomes ; hospitalisations
Heart rate ; aortic blood flow
BAT ; sympathetic outflow ; parasympa
congestive heart failure ;CHF
chromatin subproteome ; diseased mouse heart
pulmonary artery
resistin levels ; anthracycline-treated breast cancer patients ; cardiotoxicity
differential relations ; CPCs ; outcomes ; diabetes
Mediterranean ; DASH diet scores ; mortality ; heart failure
LVEF ; long-term mortality
dobutamine ; furosemide dose ; oxygen flow
miRNAs ; therapeutic targets
Jehovah's Witness ; sickle cell disease ; anemia
mRI scanner ; baseline ; heart failure
health Buddy program ; ED
clinical ; therapeutic
potent inhibition ; L-type ca2 ; currents ; Rad variant ; congestive heart failure
physician continuity
cardiac stress ; β-AR drive
PSSS ; social support
contemporary therapeutic
Frailty ; elderly
muscle-wasting syndrome ; acquired heart failure
health Buddy program ; content-driven telehealth system
bisoprolol ; mortality
ED visits ; CHF ; intubation rates
Medicare fee-for-service beneficiaries ; hospitalizations
student t test
myocardial diastolic dysfunction ;DD ; collagen deposition ; titin modification
systolic ; diastolic mitral leaflet motions
stress doppler echocardiography ; pulmonary hypertension
circulating progenitor cells ; outcome in heart failure patients
LV strain ; strain rate
septal wall CS ; free wall CS ; VVD variation
etiologic ; acute RV failure ; left ventricular dysfunction
biventricular pacing ; left heart twist ; strain ; porcine model of right heart failure
adverse events
morbidity ; mortality
serial measurements ; cPCs ; functional capacity ; heart failure
ctnt ; NT-probNP ; HF risk prediction
protein kinase ; soluble guanylate cyclase ; contractile response
HR reduction ; beta blockers ; exercise capacity
sympathetic activity ; i-MIBG myocardial washout
cohort study
cardiopulmonary exercise variables
inhospital mortality
radiological signs ; HF
outcomes ; costs
right ventricle ; RV
Mortality
RV dysfunction ; weight loss ; fat/lean body mass ratio
transcatheter
beta blockers ; heart failure
PD ; refractory ; end-stage congestive heart failure
HF ; valve plasty ; MS
pressure ulcers ; surgical patients
baseline ST2 level

therapeutic functions
Nursing-sensitive outcome change scores ; hospitalized older adults ; heart failure
black race ; mortality
regression models ; insurance status ; comorbidities
human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
social support ; barriers ; exercise adherence
NYHA
chelation regimens ; heart iron ; risk
MT ; abdominal problems
test-retest reliability ; Timed up & Go test ; patients ; advanced chronic organ failure
diagnostic procedures
follow-up visits
Thirty-day mortality
futility ; data monitoring board
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
aortic valve insufficientncy ; left ventricular assist device implantation
Left ventricular ejection time ; acute heart failure ; precapillary pulmonary hypertension
apoptosis ; pacing-induced dilated cardiomyopati
right atrium mass ; prolapse ; tricuspid valve
office of statewide health planning and development Patient discharge data
cardiac catheterization ; thrombotic obstruction ; right coronary artery
clinical ; echocardiographic ; invasive hemodynamic
HFPEF ; dietary sodium restriction ; ventricular ; vascular stiffness
functional capacity ; 6-minute walk test
chronic heart failure ;CHF ; sympathetic tone ; autonomica
CHF atrial explants ; c-Kit+ cells
magneticically Levitated Left Ventricular Assist System for Treating Advanced HF
Fontan failure ; systolic ventricular function ; liver
Heart failure ; western society ; cardiovascular diseases
figure ; hospitalized older adults ; HF
Extracorporeal membrane oxygenation ; bridge to recovery infarction-related refractory right heart failure
protein levels ; Western blot ; DNA fragmentation ; TUNEL
EH ; cardiac filling pressures
implantable cardioverter-defibrillator deactivation
Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
trastuzumab
electromechanical delay ; dyssynchronous heart failure
cardiac Mena deletion ; cardiac dysfunction ; conduction abnormalities ; hypertrophy
economic impact ; patients ; AF ; heart failure
perioperative ; early
bundle-branch block ;LBBB
BETs ; mouse TAC model ; human HF
patients ; preserved systolic function
HDL-induced NO production ; flow-mediated dilatation
implementation interventions ; uptake of class I CPG recommendations ; HF
cox regression ; cardiovascular events ; psoriasis
human heart failure ; altered protein kinase ; subunit expression
cutoff level ; NT-probNP
dopamine ; nesiriti
resource use ; quality of life ; time-varying Seattle Heart Failure
HF
patients ; aHF
chemical instability ; cogeneration of nitrite ; vascular effects
neurological ; cardiovascular event-free rate
MAD-CRT study
consultations
transfusion thresholds
Czech Republic
cardiac nurses
study closure
UM/VA/VA-RT cohorts
risk of heart failure
cost-effective ; population-specific health interventions
preoperative serum albumin levels ; survival ; left ventricular assist device implantation
western blots ; monoclonal antibodies ; Ser83 phosphorylation
treatment ; HRQoL
interleukin receptor family member ST2 ; beta-blocker therapy ; chronic heart failure
ventricular assist device ; extracorporeal membrane oxygenation ; renal function
echocardiography evaluations
exercise intolerance ; heart failure
functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Heart Association classification ; quality-of-life scores
pathophysiology ; HF ; medical management
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
Paco2 ; cerebral blood flow ; perfusion ; carotid bodies
cox models ; ST2 ; functional capacity
ED physicians ; suburban hospitals
t interventions
psoriasis patients ; smoked ; diastolic blood pressure ; body mass index
ECmo group ; VAD ; ECmo+VAD groups
beta blockers ; heart failure
anticoagulation ; underlying heart disease ; rate control
mortality ; morbidity ; cancers
energy metabolism ; heart failure ; hypertrophied heart
NT-probNP ; circulation of HF patients
ivabradine ;TAC
PAD ; ankle-brachial index
functional MS
baseline ; mechanical cardiac support ; renal function
renal dysfunction ; mechanical cardiac
device
enrollment ; left ventricular dilatation
anemia ; heart disease
CF lVAD patients ; AI ; heart failure
rhythm-control ; rate-control
heart failure
HF epidemiology ; health service provision ; HF
Functional MS ; medical treatment
study design ; hemoglobin levels
management ; ventricular assist devices
Heart failure ; debilitating chronic disease
heart failure ;HF
coagulability
exploratory factor analysis
PB ; HF
nontreatment
computing readmissions ; pay-for-performance
icd patients

HF cohort
pro-adrenomedullin ;MR-proADm ; FFM
Cardiorespiratory fitness ; body mass index ; heart failure mortality
bNP ; NT-probNP

adenyl cyclase ; differential g-protein coupling
heart failure ;HF ; left ventricular ejection fraction
Circulating fragments ; N-terminal pro-B-type natriuretic peptides ; plasma of heart failure patients
ejection fraction ; infarct size ; collateral growth ; myocardial perfusion
Heart failure ;HF
atrial fibrillation ; congestive heart failure ; cost analysis ; rhythm-control ; rate-control strategies
physical activity control ; cardiovascular risk factors ; obesity ; diabetes mellitus ; hypertension ; hyperlipidaemia
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile function
predictors of mortality ; implantable cardiac defibrillator
end-stage heart failure ; implantation ; long-term ventricular assist device
systolic HF ; unclear etiology ; coronary angography
HF ; cardiac murmurs
exercise intolerance ; chronic HFPEF ; reduced quality of life
isoproterenol ; cXL-1020 ; myocytes
Pyridostigmine ; myocyte diameter ; collagen density ; surviving left ventric
autonomic modulation ; repolarization instability ; heart failure prone ; ventricular tachycardia
cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
biventricular dysfunction ; isolated HeartMate
HF ; spontaneous VT ; beat-to beat QT intervals
social mandate
signaling pathways ; pressure-overload-induced heart failure
TUg test ; advanced COPD ; CHF ; cRF
TREATMENT ; hemodynamically unstable ; CPR
ecmo group ; egFR
sonographic ; histological ; functional abnormalities
acs procedures ; MT ; VAD
HR ; tNF antagonists ; nbDMARD
population-based Rotterdam study ; psoriasis
SCHFI ; clinical practice
energy substrate metabolism ; isolated working hearts
risk of incident CVD ; psoriasis
diabetes mellitus ; cardiovascular disease
prediction rule
general hospital ; cardiac specialty hospital
haemodynamic ; pulmonary ; peripheral abnormalities
medical records
diagnostic performance ; prediction rule
HF-related cachexia ; RV function
cognitive impairment ; mortality
hospital length ; rehospitalization
composite measure ; hospital mortality
trials ; acute HF
trastuzumab-related CHF
long-term survival
hospitals
research studies ; biomarker-guided clinical trials
sudden cardiac death ; athletes
mechanical cardiac support ; renal function ; end-stage heart failure
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
heart transplantations ;LV assist device implantations
left ventricular longitudinal systolic ; cardiovascular events ; atrial fibrillation
mouse HF model ; compensated LV hypertrophy ; HF ; HHD
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
natriuretic peptide levels ; biomarkers
sympathetic ; parasympathetic activity
bNP levels ; PAD ; bNP measurements ; HF
Spironolactone ; hyperkalemia ; acute kidney injury
chronic myocardial ischemia ; heart failure
EH ; renal impairment ; hypertension
HFpEF ; adverse outcomes
race ; outcomes ; exercise training
parasympathetic function ; slow HF evolution
Heart failure ;HF
jugular venous pressure ; peripheral oedema
aggressive medical treatment ; HF ; HF symptom
baseline Hgb ; exercise training ; KCCQ ; subscales
Surgical revascularization
pump-exchange technique ; redo sternotomy ; cardiopulmonary
clinical prediction rule ; CAD ; cause of systolic HF
Morpholino-based knockdown of nucleolin ; abolished protein expression ; gross morphological
MS ; medical treatment
cardiovascular conditions ; HF
cytoscape ; functional enrichment analysis
blacks ; hypertension ; diabetes ; ischemic etiology
NT-probNP testing ; ED patients ; acute heart failure
health insurance ; health system data partners ; u.s. Food and Drug Administration
lVAD ; biventricular support
Fontan circulation ; cardiac index
Fontan circulation ; skeletal muscle mass
hereditary ; congenital abnormalities ; heart ; nontraumatic death
hypothesis-generating findings ; mineralocorticoid receptor antagonists
normalization of albumin levels ; lVAD support ; postoperative survival
isolated HeartMate II lVAD
practice settings ; processes of care
Bisphosphonate ; heart failure ; gender-matched control
right heart circulation ; right heart failure
Raf-MEK1/2-ERk1/2 signalling pathway
early-onset ; late-onset ; MI
HF-induced remodeling aspects ; EMD prolongation
costs ; survival
sustainability ; commissioning ; hospital-based programmes
research investigations ; clinical care
national patient safety initiatives
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
Xanthine oxidase inhibition ; left ventricular systolic ; diastolic function ; cardiac volume overload
spironolactone ; systolic heart failure
nonselective ; selective beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
myocardial ischemic events ; cardiac resynchronization
β-Blockade ; cardiac angiogenesis ; heart failure ; veGF signaling pathway
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
HF ; preserved ejection fraction ;HFpEF ; hypertension
heart failure ;HF ; Heart Failure Adherence ; retention Trial
HFpEF ; fatigue ; fluid retention
Myocardial infarction ; left anterior descending coronary artery occlusion
NYHA ; quality-of-life score ; hall walk distance
aortic valve surgery ; new-onset post-LVAD
immunodetection ; NT-probNP ; antibodies
unloading of the heart ; isolated HR reduction
Nordic walking ; cardiac rehabilitation
oxidative stress ; GTPase Rac1 activity ; hearts of ANS mice
medications ; outpatients ; heart failure
cardiovascular ; urgent cardiac transplant
circulating mediator of insulin resistance ; human monocytes ; inflammatory stimuli
Heart failure ; HF
Heart failure ; atheromatous coronary disease
palliative care ; terminal phase ; advanced disease
HF hospitalization ; cRT
rehospitalization ; medicare fee-for-service beneficiaries discharged to skilled nursing facilities
diagnostic test ; HFpEF ; physical examination
trial



psoriasis ; systemic/UV
non-ischemic ; ischemic heart failure
stress conditions
heart failure ; Emergency Department ;ED ; ED volume influences patient outcomes
Intravenous iron ; iron deficiency
RV dysfunction ; weight loss ; abnormal body composition
PD ; clinical status hospitalizations ; complications of therapy ; severe end-stage HF
clinical (prognostic ; diastolic dysfunction ; HFPEF
Chromatin-associated proteins ; chromatin structure ; DNA
NT-probNP ; HF ; immunoprecipitation ; mass spectrometric analysis
right ventricle overload ; stroke volume ; left ventricular ejection time
β-Adrenergic receptor blockade ; hospitalizations ; heart failure
congestive heart failure
mitochondrial structure ; sarcomeric microstructure
CHF ; emergency department ;ED
mortality ; LCX ; LAD ; two-vessel disease model
pPR ; aCR ; CMS metrics
gut ; inflammation ; dietary interventions
practice-level differences
robot-assisted gait therapy ; Lokomat system ; heart failure patients
aIM ; implantable cardioverter-defibrillator deactivation discussions
pulmonary hypertension ;PH ; heart failure
lVET ; ICU
exertion ;therapeutic treatment ; abnormal exercise hemodynamic status
Cardiac failure ; diabetes ; heart failure
ET ; CHF-NYHA-IIIb ; HDL function
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
therapeutic interruption of activated neurohormonal systems
uptitration ; heart rate ; renal
microRNAs ;miRNAs ; pathogenesis ; heart failure
Beta-blocker dose ; resting HR
QT variability ;QTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
white rabbits ; renal DNx ; pacing-induced CHF
ambulatory HF patients ; left ventricular ejection fraction
paraDIGm-HF ; chronic heart failure Chronic heart failure
physician follow-up after discharge ; death ; readmission ; heart failure
dialysis patients ; adverse events
ZSF1 rats ; heart failure ; preserved ejection fraction
transoesophageal echocardiography ; shunts ; thrombosis
mutant mice overexpressing Hand2 ; heart muscle cells ; pathological hypertrophy
cross-talk ; heart ; adipose tissue ; cachectic heart failure patients ; body composition
arterial tonometry study ; lVET carries ; precapillary PH ; heart failure
heart magnetic resonance imaging ; chelation choices ; risk of heart disease ; thalassaemia
t1-mapping MRI ; tidal respiration ; myocardial T1 ; swine ; heart failure
processes of care delivery
internal ; external validity ; resource use ; costs

Rhythm control therapy
proteins
readmissions ; quality improvement initiative
AMI mortality rates
psoriasis ; cardiovascular disease
cutoff ; negative predictive value ; E/eseptal ; negative likelihood ratio
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
Hemoglobin ; exercise training ; health status ; chronic heart failure
RAS-blocker uptitration ; clinical outcome ; HFrEF ; HFpEF
Myocardial collagen ; collagen cross-linking ; titin isoforms ; phosphorylation
Cardiac magnetic resonance postcontrast T1 time ; heart failure ; preserved ejection fraction
LV diastolic dysfunction ; filling pressures
dRS deciles
inappropriate therapy
medical management ; HF infancy ; childhood
miRNAs ; cardiac remodeling
frailty ; risk for heart failure ;HF
heart failure ; bisphosphonates
quality of care programme ; beta-blocker therapy
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic responses
familiar physician
Plasma samples
alendronate ; risk of heart failure
transduction pathways ; signalling protein
baseline
GDMT ; BAT
risk of heart failure ; CLCNKA sNP
clinical diastolic dysfunction
acs problems ; oHT bridged to transplant ; MT ; VAD
RAS- ; β-blocker dose increase ; recommended target dose
regulation of feeding ; nutritional strategies ; anti-flammatory effects
HF ; CMS metric
Bax ; bcl-2 proteins
HF ; rheumatoid arthritis ;RA
β-Blocker-induced enhancement ; cardiac angiogenesis ; cardiac function
symptomatic adult Fontan ;SAF
natriuretic peptides ; emergency ; ambulatory
sandwich AlphaLISa ; immunoassays ; NT-probNP
cardiotoxicity ; doxorubicin ; anti-neoplastic
heart failure ; preserved left ventricular ;LV
implantable cardioverter-defibrillator deactivation
sinus rhythm ; antiplatelet agents ; anticoagulants
c-statistics ; biological phenotype ; deficit index
lifesaving drugs ; HF ; reduced ejection fraction ;HFrEF
LV diastolic dysfunction ; HFPEF
ambulatory ICD patients ; predictor ; mortality
fes ; preserved ejection fraction
Myxomas ; cardiac benign tumors
nicorandil ; cytotoxic effect ; doxorubicin ; solid Ehrlich carcinoma
Gastrointestinal bleeding
arni inhibitors ;angiotensin-receptor neprilysin inhibitors
Renal denervation ;DNx ; CHF patients
physician follow-up after discharge ; physician continuity
Crude rates ; severe hyperkalemia ; acute kidney injury ; spironolactone
Heart failure ; preserved ejection fraction ;HFPEF ; failure of cardiovascular reserve
heart failure ; elevated left atrial pressure ; hospital admission
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure
refractory congestive heart failure ; peritoneal dialysis
MT ; VAD groups ; aCS
diagnostic roles ; bNP ; NT-proBNP ; coronary artery disease ;CAD
process redesign framework
peak aerobic capacity ; left-hand grip strength ; body weight
clinical variables ; survival
circulating forms of NT-proBNP
control group
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation
heart failure-related hospitalization ; death ; preserved left ventricular ejection fraction
Kansas City Cardiomyopathy Questionnaire ; heart failure ; preserved ; ejection fraction
heart failure ; preserved ejection fraction ;HFPEF
lean ZSF1 group ; hypertensive ; obese ZSF1 groups
tissue Doppler imaging ; left ventricular filling pressure ; severe systolic heart failure
Heart failure ; preserved ejection fraction ;HFpEF
myocardial PDE2 ; intracellular antiadrenergic strategy ; HF
shortened lVET ; ICU admission ; precapillary PH ; heart failure
myocardial loss ; IRS1 ; iRS2 ; heart failure ; p38alpha MAPK ; insulin resistance
heart failure mice model ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
transfusions ; heart disease
PVF ; ascending phase ; PB cycle ; recovery period of low BP
sST2 ; low-dose BB ; cardiovascular event rate
eCG parameters ; CRT
remote monitoring ;RM
RV dysfunction ; cardiac cachexia
chronic heart failure ; Hungary
HF hospitalization
exercise ; diet ; peak VO2
spironolactone ; clinical practice
carotid intima-media thickness
coronary occlusion ; collateral growth
mechanical dyssynchrony ; narrow QRS complex
pharmacologic treatment ; clinical trials
time-dependent analysis ; IE ; risk ; heart failure ;HF
breast cancer patients ; trastuzumb-related CHF
pde2 ; failing hearts ; desensitizes against acute β-AR stimulation
anemic ; iron-deficient adult patients ; heart disease
Point-of-care systems ; NP levels ; ED ; community outpatient settings
EO-CFUs ; reduced mortality
trastuzumab ; CHF
low eGFR ; need of diuretics ; uncontrolled hypertension ; ESRD
heart failure ; hospitalisation
acute heart failure ; aHF
psoriasis patients ; general population ; atherosclerosis ; cardiovascular events ; psoriasis
HF remodeling aspects ; EMd ; dyssynchronous failing heart
aggressive dose uptitration
anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HF ; hypertension ; vasodilators ; diuretics
aldosterone antagonist ; heart failure
angiogenesis ; post-myocardial infarction heart ; progression to heart failure
heart failure ; preserved ejection fraction after myocardial infarction
single-arm
HDL function ; CHF ; ET ; HDL-mediated vascular effects
HF risk factors ; fit ; HF mortality
implementation strategies ; physician adherence


black race ; HF hospitalization ; cardiovascular mortality
coronary artery disease ; systolic heart failure
arterial compliance ;TAC ; end-systolic elastance ; ees
Renal dysfunction ; all-cause mortality ; cardiovascular events
isoprenaline infusion ; SDQT ; HNorm
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery ; HFpEF
Renal dysfunction ; myocardial infarction ; coronary artery bypass grafting
biventricular support ; HeartMate II lVAD ; CentriMag RVAD ; hospital discharge
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic ; general anaesthesia
dopamine ; nesiritide
Clinician interviews ; nonprescribing ; chart review
biomedical reasons ; nonprescribing
ERC ; pure epicatechin
care management ; content-driven telehealth technology ; high-cost Medicare beneficiaries
ea ; TAC ; HR ; ees ; ivabradine ; placebo-treated patients
HF
CHF ; international classification of Diseases
MEDline ; EMBASE ; cochrane databases ; clinical trial registries ; technical advisors
egFR ; VAD group ; ECMO group
idiopathic dilated cardiomyopathy cohort
cardiac growth ; plasticity ; disease recapitulates ; developmental chromatin remodeling events
Robot-assisted gait therapy ; Lokomat® system
baseline ; HF mortality risk ; HF risk factors
RV dysfunction ; lower body mass index ; fat mass index ; cachexia
myocardium displays altered expression ; post-translational ; PKA subunits ; downstream signaling
s3991 ; elastic N2Bus segment ; s12884 ; PEVK segment
quantitative proteomics ; chromatin-associated proteins extracted ; detergent
cXL-1020 converts ; Hno ; inactive CXL-1051
arterial elastance ; ea ; pulsatile afterload ; heart ; pressure volume relation
pharmacologic management ; acute HF ; adverse event rates
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats
HeartMate 3 left ventricular assist system ; lVAS
grounded theory ; heart failure patients ; implantable cardioverter-defibrillator
Self-Care of Heart Failure Index ;SCHFI v.6.2
atrial fibrillation ; carvedilol
heart failure ; mechanical support devices ; Cardiology-Cardiovascular Surgery Consensus Report Heart failure ; progressive disease
ST-segment-elevation MIs ; Killip class
management of end stage heart failure ; public health problem
HeartMate II insertion ; biventricular support ; HeartMate II implantation
functional MS ; valve plasty ; degenerative MR
tNF antagonists ; HF hospital admissions ; nbDMARDs
physician adherence ; class I recommendations
voluntary testimonies ; conversations ; nurses
risk-adjusted mortality
exercise ; diet
GLS ;HR
ejection fraction
epidemiology ; myocardial infarction ;MI ; heart failure
Heart rate reduction ; exercise performance in recent onset heart failure ; reduced ejection fraction ; beta-blocker hypo-response
Isoelectric focusing ; RIα ; ser77 ; ser83
baseline NT-probNP ; MR-proANp ; MR-proADm
mADIt-cRT ; multicenter Automatic Defibrillator Implantation ; Cardiac resynchronization Therapy
serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
RAS ; hypertension ; nephropathy ; congestive heart failure
SDQT ; SD ; RR intervals ; QTV normalized ; heart rate variability
cardiac magnetic resonance imaging ; T1 mapping ; invasive hemodynamic assessment
HF under drug treatment ; PAF biosynthetic enzymes ; lyso-PAF-AT
cardiac events
sST2/low-dose BB ; high sST2/high-dose BB
HF complicating AMI ; high mortality
LV ejection fraction ; PCWP
Validation studies ; zebrafish ; Nucleolin ; genomic reprogramming events ; development ; disease
physical volume ; HF ; low-volume institutions ; noncardiologist
CHF visit rates ; ED visits
Logistic regression models ; primary outcome ; secondary outcome of death ; cause
egFR ; VAD group ; ECMO+VAD group ; renal function
e/eseptal ; e/emean ; s'septal ; QRS width
gastrointestinal bleeding
hospital ; readmission rate ; heart failure
diuretics ; HF-related morbidity
congestive heart failure
IVc occlusion ; twist ; apical rotation ; RS synchrony
emergency department ; acute heart failure clinical trials ; enrollment
heart failure ;HF ; risk stratification models
carvedilol ; metoprolol ; heart failure patients
BET bromodomain-containing protein 4 ;BRd4
in-trial resource utilization ; unit costs ; Québec health insurance board databases ; disease-specific costs ; Ontario case costing Initiative
mitral valve plasty ; degenerative mitral regurgitation
intravenous iron ; exercise tolerance ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
public health ; air pollution ; industrial areas
molecular biomarkers ; pathophysiology ; chronic HF
cardiopulmonary exercise test ; performance ; muscular strength ; peak quadriceps force
HF ;heart failure ; t2d ; type 2 diabetes ; Skm ; skeletal muscle
Morbidity ; mortality ; HFpEF
HF rats ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control of heart rate
idiopathic dilated cardiomyopathy ; Tuscany
eCG ; congenital accessory pathways ; ion channelopathies ; cardiomyopathy
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction
AF ablation
ejection fraction
echocardiographic score ; predicting CRT response
economic models
center retrospective observational study ; end-stage heart failure ; pediatric mechanical cardiac support
readmission rate ; initiative
t1-mapping sequence ; tidal respiration ; gadolinium-chelate contrast agent
Medicare inpatient data ; HF admissions
HF ; preserved ejection fraction ;pEF ; uptitration
mouse HF model ; HHD ; salt loading ; uninephrectomy ; ANG II infusion
DAPC ;dystrophin-associated protein complex
dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction
catheter ablation of atrial fibrillation ; heart failure
Myocardial titin hypophosphorylation ; heart failure ; preserved ejection fraction ; rat metabolic risk
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
If-channel inhibition ; hemodynamic status ; exercise tolerance ; heart failure ; preserved ejection fraction
RV failure ; management strategies ; intrinsic left ventricular dysfunction
Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
trends ; HF ; MI ; preserved ; reduced ejection fraction

HeartMate II lVAD ; temporary CentriMag RVAD
HFpEF ; KCCQ ; health status
baseline serum creatinine level ; serum potassium level
PD initiation ; weight loss
echocardiographic predictors ; response after cardiac resynchronization therapy ;CRT
circulating NT-probNP concentration ; antibodies targeting nonglycosylated ; nonterminal epitopes
University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
anemia ; chronic heart failure ;HF
Hum-Retn mice ; cardiac mRNA levels ; inflammatory ; cell adhesion genes
chromatin subproteomes ; heart failure ; mechanisms ; chromatin structure
nbDMARD ; tNF antagonist
HFrEF ; exercise performance ; resting HR ; beta-blocker therapy
XO inhibition ; cardiomyocyte bioenergetics ; LV function ; chronic ACF ; rat
heart failure nurses ; cardiology services
heart failure ;HF ; maximal cardiopulmonary exercise test ; anaerobic threshold
preoperative renal dysfunction ; early risk of stroke ; myocardial infarction ; heart failure
cox hazard models ; time to ESRD ; to death ; composite end point of ESRD ; death ; predictors of ESRD
randomised-controlled trials ;RCTs
pyridostigmine administration ; methylatropine ; propranolol
pf ; metabolic enzymes ; heart failure ; healthy volunteers
trastuzumab ; adjuvant setting ; cardiotoxicity ; congestive heart failure
carvedilol ; thromboembolic events ; heart failure
Phosphodiesterase-2 ; human failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
echocardiographic ; N-terminal pro-brain natriuretic peptide ; inflammatory markers
myosin binding protein-C phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
uPR effectors ; protein kinase R-like ER kinase ;perk ; calreticulin ; CHOp
HF rats ; pyridostigmine ; ejection fraction ; cardiac output ; contractility ; left ventricle

deactivation
nutritional abnormalities ; CHF
costs ; high-volume physicians
doxorubicin ; ip ; serum resistin levels ; Hum-Retn mice
vena cava ;IVC
direct observation ; rheumatic ; MS
post-HCT CHF
middle-aged recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
Peak consumption ; oxygen pulse
dialysis-dependent patients ; HF ; cRT implantation
structure ; function ; RV
CHF-developed infarcted animals ; left ventricle end-diastolic pressure
Women' health Initiative ; HF hospitalization
economic climate ; NHS ; behavioural-change interventions ; chronic disease ; exercise programmes
aldosterone receptor antagonists ; morbidity ; mortality ; symptomatic systolic heart failure
CV deaths ; non-fatal stroke ; hospitalisations ; heart failure
biomarkers ; molecular dysfunction ; chronic HF
air pollution ; cardiovascular health
VAD group ; ECMO+VAD group
non-ischemic ; ischemic heart failure
gls ; index beat method ; CV events ; cox proportional hazards
reclassification of risk ; C statistic ; net reclassification ; discrimination improvement
east ; rhythm control therapy ; AF
hearts ; Mena ; cardiac injury ; HF
scn5a transcript ; uPR ; downregulation ; cardiac genes ; HF
lipolysis ; energy expenditure ; natriuretic peptides ;NPs
cox proportional hazards models ; demographics ; health behaviors ; health status
tAPse ; PASP relationship ; downward regression line shift ; nonsurvivors
right ventricular ;RV ; left ventricular assist device ; lVAD
albumin levels ; inflammation ; hepatic function
KccQ ; Kaplan-Meier curves ; death ; all-cause hospitalization
Olmsted County ; Minnesota ; MI diagnosed ; HF
medical hospitalization ; HF
prediction rule ; CAD
inhibition of vascular endothelial growth factor ;VEGF
left ventricular ejection fraction ; long-term mortality ; heart failure
neurohumoral blockers ; HF hospitalization ; co-morbidity burden
temporal incidence ; odds ratio ;hazard ratio ; death ; HF ; AMI
testosterone therapy ; exercise rehabilitation ; chronic heart failure ; low testosterone status
health Buddy program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
IC enrolled ; Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
global proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
AMI ; heart failure ; kidney infection ; UTI
renal underperfusion ; renin- angiotensin-aldosterone pathway
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
HR dynamics ; time-domain ; spectral ; HR variability
cRT-D ; IE risk ; defibrillator-only therapy
patients ; diagnostic procedure
occurrence ; HF ; index AMI
apoptosis ; pathogenesis of heart failure
BETs ; transcriptional pause release ; transcription
lVAD ; transplantation eligibility status
LVEF
uPR ; na+ channel mRNA splice ; cardiac na+ current ; human HF
diuretic efficacy ; adverse neurohormonal activation ;congestion-like
eCG ; atherosclerotic CAD ; sudden cardiac death
obesity ; diabetes mellitus ; metabolic risk factors ; comorbidities ; heart failure ; preserved ejection fraction
Cardiopulmonary exercise testing ; echocardiographic assessment ; myocardial function ; left ventricular filling
percutaneous coronary revascularization ; hemodynamically
atrial fibrillation ; atrial tachyarrhythmias
speckle tracking echocardiography ;STE ; biVP ; right ventricular pressure overload ;RVPO
dose uptitration ; HR reduction
ANS mice ; LV fractional shortening ; lung weight
mechanism enrichment analysis ; programmed cell death
dysfunction ; naturally occurring Rad variant ;Q66P ; congestive heart failure
incident systolic heart failure ; spironolactone
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension
perk inhibition ; full-length sCN5A ; Kv4.3 mRNA levels ; na+ channel mRNA splice
bottleneck stent ; timing of myocardial infarction ; antiplatelet medication
sex ; EF ; bNP ; HF patients
atrial fibrillation ;AF ; heart failure ;HF ; progress in anticoagulation
echocardiographic score ; LV reverse remodeling
salt loading ; uninephrectomy ; ANG II infusion mouse model ; cardiac function ; mice
Mena expression ; HF ; human ; animal models ; Mena ; cardiac pathophysiology
LVEF ; long-term mortality ; acute decompensated HF
atrial fibrillation
controlled randomized trial
NP measurement ; POC measurement ; NPs ; clinical care delivery
figure ; intestinal morphology ; permeability ; absorption function
high-volume physicians ; readmission rates
divergent etiology ; comorbidities
proteins ; cardiac hypertrophy ; failure
peak work rate ; peak quadriceps force
myocardial DD ; high muscle strip stiffness ; titin hypophosphory
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
exercise ; anaerobic metabolism
idiopathic dilated cardiomyopathy
fibrosis ; heart failure myocardial tissue ; left ventricular tissue ; trichrome blue histologic
Kansas City cardiomyopathy Questionnaire ;KCCQ ; HF ; EF ; HFpEF
Blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume
biventricular support ; HeartMate II lVAD ; CentriMag right ventricular assist device
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure relationship ; heart failure ; right ventricular contractile function
right ventricular ;RV ; body composition ; advanced heart failure
American College of Cardiology/American Heart Association guidelines on evaluation and management ; patients ; RAS
Frailty ; heart failure ;HF
functional MS ; valve plasty ; annular size reduction ; degenerative MR
implantable cardioverter-defibrillator deactivation discussions
EO-CFUs ; lower CD34+VEgFR2 ; cells ; nondiabetic patients
functional MS ; valve plasty ; degenerative MR ; LV
exercise training ; HF patients
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ;ECMO
sNP rs10927887 ; Ka renal chloride channel gene ;CLCNKA
Circulating progenitor cells ;CPCs ; endothelial repair ; cardiovascular diseases
HF-ACTION cohort ; baseline Hgb ; baseline HRQoL ; KCCQ
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; inflammation
NT-probNP levels ; plasma ; dyspnea ; left ventricular dysfunction
contractile function ; LV dilatation ; LV end-diastolic pressure/wall stress ; lung weight
LV remodeling ; diastolic properties ; XO inhibition ; hospitalizations ; severe heart failure
virtual cohorts ; resource ; costs ; survival
patients ; borderline ; female ; preserved
blood pressure control ; goal-directed lipid-lowering therapy ; smoking cessation
SDQT ; HFVT ; HFVT ; HNorm group ; fixed-rate atrial pacing
bTT ; DT ; cost-effectiveness limits
expenditure ; health per capita ; gross national income per capita ; HF
is ; cRT-D recipients ; risk ; heart failure
bNP ; inhospital mortality
t1-mapping technique ; diffuse myocardial changes ; heart failure ; contrast agent
AF
RAS- ; β-blocker uptitrations ; HFrEF ; HFpEF
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma
HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
low-sodium DASH ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; preserved ejection fraction
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling in heart failure
implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ;CRT
frail ; biological phenotype
HFPEF ; longitudinal outcome-monitoring phase
LBBB ; implantable cardioverter defibrillator-CRT
standard error of measurement ; mDC
embryonic gene programs ; pathological heart disease ; transcription factors
acute heart failure ; aHF
recharged ; unplanned admission
skeletal muscle sarcomere structure ; heart failure ; type 2 diabetes ; epicatechin-rich cocoa
QRs morphology ; duration ; cardiac resynchronization therapy
exercise-induced PASP ; low PASP
sST2/low-dose BB ; high sST2/high-dose BB ; cardiovascular events
mitochondrial complex V activity ; aac ; ratio of phosphocreatine to ATP
eplerenone ; HF-REF ; inducing hyperkalemia ; WRF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths
Physician volume ; patients undergoing procedures
isolated heart rate ;HR ; ivabradine ; afterload ; systolic heart failure
biomedical treatment ; CHm ; dCM ; heart failure
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;CORAL ; stenting ; RAS
Yorkshire swine ; pacemakers ; ventricularly paced
echocardiographic score ; reverse remodeling after CRT
Mediterranean ; Dietary Approaches to Stop Hypertension ;DASH ; mortality ; postmenopausal women ; HF
therapeutic left-to-right interatrial shunting ; heart failure
mortality ; heart failure ;HF
heart failure ; severe hypertension ; mitral regurgitation ; mitral stenosis
ST2 ; cardioprotective signaling ; myocardium ; biomarker ; heart failure
cardiovascular ; stroke ; heart failure ; myocardial infarction
mi ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
exercise-induced PASP increase ; pulmonary hypertension patients ; right ventricular contractile reserve
implantable cardioverter-defibrillator ; Heart Function Clinic ; university health network
perk activation destabilized SCN5A ; Kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
Cardiac-resynchronization therapy ;CRT ; morbidity ; mortality ; chronic systolic heart failure
renin-angiotensin-aldosterone ; sympathetic nervous systems
NP levels
design ; factorial trial
quality of life ; functional capacity
electronic databases ; MEDLINE ; EMBASE ; PsycINFO
echocardiography ; cardiac diameters ; b-treated rats
LBBB ; QRS ; implantable cardioverter defibrillator-CRT
patient-level regression ; risk-adjusted mortality ; readmissions ; costs
international right Heart Foundation Working group ; defects ; syndrome of right heart failure
HF risk factors ; HF epidemiology ; SH ; c'd ; rheumatic fever
mice ; cardiac myocyte-specific Mena overexpression ;TTA/ttttMena
HFpEF ; diastolic filling time ; controlling heart rate
guideline-recommended medications ; heart failure ; reduced ejection fraction
chronic heart failure ;HF ; purely hemodynamic disorder ; syndrome ; dysfunction ; molecular pathways
caloric restriction ; aerobic exercise training ;exercise ; QOL
antiplatelet agents ; anticoagulants
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance
data processing ; differential analysis
follow up body weight ; FM
financial burden
cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction
outpatient assessments ; patients ; heart failure ; hospital discharge ; readmissions
interagency Registry for Mechanically Assisted Circulatory Support
truncated na+ channels ; unfolded protein response ; uPR ; sCN5A electric remodeling ; HF
crude ; ankle-brachial index ; pulse-wave velocity ; coronary artery calcium
myofiber dynamics ; myofiber shortening ; EMd ; dyssynchronous HF
Fontan failure ; hemodynamically ; traditional heart failure ; systemic vascular resistance ; sVR index ; preserved cardiac index
allopurinol ; contractile function ; efficiency ; XO-mediated ROS effects ; myofilament Ca(2+) sensitivity
baseline Hgb ; baseline KCCQ scales ; Hgb ; exercise training on HRQoL
ventricular ejection fraction ; left ventricular diastolic end diameter
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenes ; failing heart
ventricular ejection fraction ; heart failure ; preserved ejection fraction
ecntric ; concentric left ventricular hypertrophy ; heart failure ; preserved ejection fraction
isolated heart transplant
median rate ratio
ET on HDL-mediated protective effects ; molecular pathways ; chronic heart failure
physical activity ; HF mortality
metabolic exercise ; cardiac ; kidney index score
heart failure ; refill compliance ; etidronate ; alendronate
rehospitalization ; Medicare ; post-acute care transfer policy
physicians ; advanced heart failure
logistic regression analysis ; high BNP ; ec/e ; diastolic dysfunction
systolic function ; HFpEF patients ; long axis function ; exercise
scn5a variants ; angII ; hypoxia ; exogenous variants induced uPR ; downregulation ; na+
NT-probNP assay ; nonterminal epitopes ; central glycosylated region
g-protein-coupled receptor kinase-2
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
concurrent HF ; 28-day mortality
low-dose dopamine ; nesiritide ; decongestion ; renal function
alendronate ; etidronate- ; raloxifene-treated
diagnostic ; clinical trials
implantable cardioverter defibrillator-CRT ; non-LBBB
KCCQ domains ; HFpEF ;Cronbach ;
anemia ; iron deficiency ; MEDLINE ; cochrane Library
HART ; HFpEF ; HF ; reduced ejection fraction ;HFrEF
perturbed bone morphogenetic protein 4 expression ; rRNA transcription ; heterochromatic chromatin
left ventricular assist devices ; lVADs
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialys
Extracellular matrix ; left ventricular biopsies ; tissueFAXS technology ; t1 time
elevated resistin ; anthracycline-induced cardiotoxicity ; heart failure ; macrophages
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis/gluconeogenes ; citrate cycle
ST2 ; clinical variables ; amino-terminal pro-B-type natriuretic peptide
tachypacing-induced HF ; contractility ; end-systolic elastance ; venoarterial dilation
Chemotherapy ; trastuzumab use ; comorbidities ; CHF ; international classification of Diseases ; healthcare Common procedure codes
contemporary heart failure ;HF
performance ; extreme deciles ; level of agreement
sST2 ; low-dose BB
saxagliptin ; sitagliptin ; follow-up data
t1 changes ; myocardial collagen ; traditional myocardial delayed enhancement imaging
Sprague-Dawley rats ; sham ; ACF ; allopurinol
cardiac plasma membrane levels ; s1PR1 ; overstimulation ; heart failure
neurohormones ; adipokines ; body composition ; CC ; progressive loss of fat free mass ;FFm ; fat mass
fully magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure model-predicted survival
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
biventricular pacing ; biVP ; cardiac output ;co
Myocyte hypertrophy antecedent to heart failure ; global gene expression
expression ; mistargeting ; regulation ; Rad Q66p ; RGK protein
serum levels ; creatinine ; BNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
AlphaLISa immunoassays ; antibodies ; extreme N ; c termini ; circulating NT-probNP
New York Heart Association ;NYHA ; chronic heart failure ; reduced ejection fraction
Catheter ablation for AF ; compensated HFPEF ; left ventricular ;LV
transplantation ; consultation ; operation
cRT group ; control group ; hazard ratio
cardiomyocytes ; mechanical ; humoral stimuli ; myocardium ; workload
BB therapy ; sST2 measurement ; chronic heart failure
biventricular support
hano donor ; myocardial ; HF
TUnel assay ; apoptotic cells ; TUNEL-positive cells
length-force relationship ; RV function evaluation
ESRD ; outpatients ; systolic HF ; eGFR
congestive heart failure ; non-urbanized Midwestern state ; South Dakota
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure
cox proportional hazards models ; score ; death ; transplantation ; LV assist device implantation ; heart failure
race ; exercise training ; chronic heart failure ; controlled Trial Investigating Outcomes in exercise TraiNing
risk for Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
intraclass correlation coefficient ;ICC ; kappa coefficient ; standard error of measurement ; mDC
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
biological phenotype ; deficit index ; medical records
cardiology practices ; national Cardiovascular Disease Registry practice innovation ; Clinical Excellence registry
tachycardia ; intravenous atropine ; cardiac vagal tone
CHF ; cardiac explant c-Kit ; progenitors
transitions of care program
surgically induced myocardial infarction ; heart failure rats
sts HH ; medical support ; office hours ; all-cause mortality ; discharged patients
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure
SDQT ; HFVT ; HNorm group ; acute β-adrenoceptor blockade ; esmolol
heart failure ; preserved ejection fraction ;HFPEF ; heart failure ; overweight
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
STUDY DESIGN ; 30-day readmission rates ; heart failure ;HF ; acute myocardial infarction ;AMI
Peripheral artery disease ;PAD ; heart failure ;HF
echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
Renal dysfunction ; heart failure ;HF ; renal disease ;ESRD
hano donor ; isolated myoctyes ; intact hearts ; heart failure
drug-free
protocol-driven POC testing ; NP ; patient consultation ; ED
shuttle walk test ; body mass ; hand grip strength
physician volume ; mortality ; internists
histological analysis ; capillary ; coronary perfusion ; ad-Flk rats ; b-treated ; ad-C rats
strength of race ; contemporary chronic heart failure ;HF
leaflet configurations ; serial evaluation ; MS ; subvalvular ; dynamic
clinical characteristics ; heart failure ; CHARM programme ;Candesartan in Heart Failure Assessment of reduction in Mortality ; Morbidity
udirectional left-to-right interatrial shunting ; patients with heart failure ; reduced ejection fraction
heart failure ; left ventricular ejection fraction
Nicorandil ; decrement of heart rate ; aortic blood flow ; mitochondrial oxidative stress induced ; doxorubicin cardiotoxicity
aldosterone antagonist therapy ; chronic advanced heart failure patients ; post-myocardial infarction heart failure patients ; reduced ejection
myocardial extracellular matrix ; cardiac magnetic resonance T1 ; pathobiology/pathophysiology
bmi ; weight ; heart rate ; rhythm ; lying ; standing blood pressure ; auscultation ; valvular disease ; pulmonary congestion
preoperative renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure
Troponin T ; N-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis risk
exercise ; cell senescence ; active individuals ; malignancies ; cancer ; prostate ; colon ; osteoporosis
asymptomatic pediatric Fontan ;PF
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
chronic heart failure ;CHF ; explant-derived progenitor cells
anemia ; HF ; health-related quality of life ;HRQoL
Lancet ; air pollution ; heart failure ; high morbidity ; mortality
ventricular assist devices ; units accustomed ; cardiac nurses ; management of gastrointestinal bleeding
American College of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
cardiac transplant (ECCT ; transplant pool ; donors ; recipients ; transplant process
MI-induced decreases ; septum ;systolic ; thickness ; LV posterior wall thickness ; LV internal diameter
HR variability ; mortality ; AMI ; CHF/LV dysfunction
BAT ; pro-brain natriuretic peptide
HF registry
economic analysis ; Patient Management Interventions in Heart Failure cost-Effectiveness model ; cost-effectiveness ; disease management programs in heart failure
obese ; HFPEF ; caloric restriction ; aerobic exercise training
acute RV failure ; chronic pulmonary arterial hypertension ;PAH ; acute pulmonary embolism
baseline SDQT-to-SDRR ratio ; HFVT ; HFVT ; HNorm groups
ventricular structure ; both geometry ; fiber/sheet orientation ; ca(2+) handling ; slowed conduction ; wall stiffness
Rad Q66p ; cardiomyopathy
sST2 titrated ; high-dose BB ; cardiovascular event rate
serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
acute RV failure ; pulmonary embolism
exercise ; medical Therapies ; Cardiac Function ; shortness of Breath Due to Lung Congestion
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
mortality ; mortality ; cardiovascular mortality ; HF hospitalization
cox regression ; spironolactone ; death ; hospitalization ; severe hyperkalemia ; acute kidney injury
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers
Fractional flow reserve measurements ; positron emission tomography imaging ; severe ischemia ; bottleneck stenting ; left ventricle ; proximal LAD model
cardiac resynchronization therapy ;CRT ; mild heart failure ;HF ; QRS prolongation ; ejection fraction
Neprilysin inhibitors ; natriuretic peptide system ; breakdown of atrial natriuretic peptide ; b-type natriuretic peptide
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure patients ; preserved left ventricular ejection fraction
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; preserved left ventricular ejection
Chinese herbal medicine ; adjunctive treatment ; dilated cardiomyopathy ;DCM ; heart failure
postoperative ; preoperative hypoalbuminemia
nurse assessment of cognitive impairment ; hospitalization ; physician ; discharge ; elderly patients hospitalized ; heart failure
bisphosphonates ; alendronate ; etidronate ; risk of heart failure
Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INV group ; sham-INV ; sham levels ; renal DNx
patients ; advanced heart failure ;heart team
left bundle branch block ; electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
HF-ACTION ; HF ; ejection fraction ; usual care
hypertension ; diabetes mellitus ; systolic murmurs
TAPse ; PASp relationship ; nonsurvivors ; HFrEF ; HFpEF
in vivo inhibition ; miR-25 ; antagomir ; spontaneous cardiac dysfunction ; murine myocardium to heart failure
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; cumulative administration of doxorubicin
haematopoietic cell transplantation ;HCT ; congestive heart failure ;CHF ; pre-HCT exposure to anthracyclines
NT-probNP levels ; acute HF
epigenetic ;writer ; proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development ; disease
carvedilol ; β-blocker metoprolol ; thromboembolic events ; heart failure
baseline characteristics ; cardiac transplant survival
measures of quality ; HF ; AMI ; pna ; future mortality
dietary recommendations ; heart failure ;HF
arrhythmia substrate ; AMI ; HR variability
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate controls ; human resistin
hypertension ; compensated HFPEF ; DASH/SRD ;target sodium
deranged ca(2+) handling ; extending EMd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF
ejection fraction ; cardiac index ; inotropes ; inotrope
high-density lipoprotein ;HDL ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide ;NO
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure samples ; healthy control
insulin resistance ; type 2 diabetes ; insulin receptor substrates ;IRS1 ; IRS2 ; insulin-signaling components regulating cellular metabolism
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing Outcomes Classification
8-fluo-cAMP binding ; wild type ; phosphomimic Ser77 ; ser83 mutant RIα proteins ; double mutant ; WT RIα
preoperative albumin ; mortality ; lVAD implantation
systolic heart failure ; QRS duration ; cRT ; rate of death ; hospitalization ; heart failure
cox regression models ; propensity score decile ; oral glucocorticoid ; HF hospitalisations ; loop diuretics
Functional electrical stimulation ;Fes ; exercise capacity ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
Dialysis patients ; HF hospitalization ; HF hospitalization
reoperation ; bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; mortality ; readmissions in heart failure ; ejection fraction ;HFrEF ; heart rate
dyssynchronous HF ; electromechanical delay ;EMd ; local myocyte depolarization ; myofiber shortening onset
QRs morphology ; outcomes after cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial
statistical standards ; biomarker-guided clinical trial design
SAF cohort ; abnormal liver texture changes
transplant ineligible patients ; HF volume management ; clinical ; post-PD initiation
Frailty ; biological phenotype ; weak grip strength ; physical exhaustion ; slowness ; unintentional weight loss
cRT-D ; IE ; IC
discharge ; heart failure home ; low-volume ED cases ; readmissions ; repeat ED visits
acute right heart failure ; therapy refractory cardiogenic shock
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
guidelines ; office-based ; emergency room practice
heart magnetic resonance imaging ; chelation choices ; patient compliance
ejection fraction ;EF ; pre-PD
cPCs ; early-outgrowth colony-forming units ;EO-CFUs ; circulating CD34 ; vEGFR2 ; CD133
Gene expression ; Bax ; bcl-2 mRNA expression ; moderate heart failure ; bcl-2/Bax
nitroxyl ;hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation
clinical effects ; cost-effectiveness ; continuous-flow lVADs ;HeartMate II ;HM II ; HeartWare ; bTT ; DT
baseline EF ; EF ≤30%
skeletal muscle mass assessed ; relative appendicular lean mass index ; age-matched ; sex-matched
DASH ; mortality ; HF
quality of life ; all-cause mortality
bNP ; inhospital mortality
cardiovascular diseases ; heart failure ;HF
heart failure attributable ; left ventricular systolic dysfunction
CLCNKA polymorphism ; p.Arg83Gly ; heart failure ; glomerular filtration rate ; RENAStur cohort
ST2 ; functional capacity ; well-treated cohort of ambulatory patients ; HF
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; b-treated ; drug-untreated failing hearts
cultured cardiomyocytes ; JQ1 ; drug abrogated ; phenylephrine-induced genes
exercise-induced PASP ; right ventricular contractile reserve
Gene expression profile gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure samples
cardiac insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
baseline ; post-DASh/srd brachial ; central blood pressure ; radial arterial tonometry ; echocardiographic measures
psychosocial Factors ; exercise adherence ; outcomes ; Heart Failure Patients ; HF-ACTION
derivation cohort ; coronary angiography ; systolic HF of unclear etiology
arterial elastance ; ea ; end-systolic elastance ; ees ; ventricular-arterial coupling
antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
angiotensin II ; angII ; hypoxia ; activators ; abnormal SCN5A mRNA splicing ; overexpress SCN5A variants
HF ; reduced ejection fraction ;HFrEF ; HF ; preserved ejection fraction ;HFpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; Fes ; exercise capacity ; emotional status ; endothelial function ; HFpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene ; mechanism of action
hearts ; TTA/tttttMena mice ; wild-type littermates ; heart mass ; transgenic mice
; onset HFrEF ; standardized exercise protocol ; respiratory gas analysis
guideline-recommended drugs for heart failure ; chart review ; biomedical reasons
wasting ; lean mass ; adverse outcome ; fat loss ; enhanced catabolism ; adipose tissue
hearts of fish lacking Nucleolin ; developmental impairment ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
black race ; chronic HF ; modifiable risk factors ; HF hospitalization ; mortality ; exercise training
adverse event rates ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-Retn mice ; doxorubicin in vitro ; hRetn ; human resistin mRNA ; protein expression
lVADs ; CF devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD devices ; HeartWare intl ; Framingham
FM ; plasma NPs ; total adiponectin
withdrawal of sympathetic tone ; parasympathetic tone ; heart rate response ; intravenous bolus of metoprolol
EH denotes ; HFpEF ; HF ; EF ;HFrEF ; HFrEF therapy
HF patients ; immunoreactive NT-probNP ; N- ; c-terminally truncated fragments ; NT-probNP
beat-to-beat QT interval
statistical ; limits of agreement
power spectral analysis ; low-frequency ; high-frequency ;LF/HF ratio ; CHF-INV ; sham-INV ; sham levels ; DNx
contractility ; ventricular-arterial coupling ; ivabradine
follow-up visits
N-terminal pro-B-type natriuretic peptide ;NT-proBNP ; misdiagnosis of heart failure
cardiac magnetic resonance postcontrast T1 time ; HFPEF
HF-ACTION ; left ventricular ejection fraction ; New York Heart Association class II ; IV HF ; exercise training
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic ZSF1 rats ; heart failure ; preserved ejection fraction
transcriptional analysis ; cardiac tissue ; mice ; TAC- ; sham-operated ; JQ1 ; vehicle ; BET inhibition ; pathological cardiac gene expression programme
cox-proportional hazard models ; negative binomial regression models ; intervention ; survival ; utilization
systolic blood pressure ; left ventricular ;LV ; hypertrophy
conditional gene-targeted Hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
admission NT-probNP ; prescriptive 4-year survival ; patients admitted ; ED ; acute HF diagnosis
Peak oxygen consumption ;VO2max ; resting HR
follow-up ; heart failure ; sudden death ; noncardiac ; cardiac transplant
frailty ; health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; incident HF
epigenetic readers in cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; HF progression
clinical prediction rule ; CAD ; angiography ; systolic HF
load-corrected chronotropic response ; heart rate
gastrointestinal bleeding ; incessant ventricular tachycardia storm ; terminal heart failure
Catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d consumed ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; reverse remodeling
RV support ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail participants ; severe frailty ; Gill index ; HF
between ; HF ; AMI
Chronic heart failure ;CHF ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance
Chronic β-AR stimulation ; catecholamine infusions ; rats enhanced PDE2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
chronic PAH ; hospitalized patients ; acute RV decompensation ; pharmacologic therapies
obese ZSF1 groups ; heart failure ; preserved ejection fraction ; lung weight ; preserved left ventricular ejection fraction ; left ventricular
Xanthine oxidase ;XO ; human ; rat left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula
free-breathing pulse sequence ; myocardial T1 changes ; swine model of tachycardia-induced heart failure
PF cohort ; New York Heart Association classes
comanagement ; patient preferences ; nonadherence ; clinician belief ; medication
high-volume physicians ; low-volume physicians
western Australian linked administrative health data ; HF hospitalized ; index ; AMI
consensus report
ecs ; heart failure
nursing-sensitive outcome measures ; experimental research
miRNAs ; noncoding RNAs ; regulate expression of target genes ; sequence-specific binding ; untranslated region of messenger RNA
HFpEF ; ivabradine
Cardiac c-Kit ; cardiac explant-derived cells ; cardiac functions ; myocardial infarction
NPs ; pulmonary embolism ; diabetes
pathophysiology ; HF ; medical management
empirically derived composite quality measure ; heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
mortality ; healthcare utilization effects ; care management ; telehealth ; congestive heart failure ; chronic obstructive pulmonary ; diabetes mellitus
inhibitor JQ1 ; BETs ; chromatin ; downstream signalling ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction
epidemic ; heart failure ; preserved ejection fraction ;HFpEF ; health status
cox proportional hazards regression modeling ; risk factors ; i ; acute coronary syndromes ; coronary interventions
diminished cyclic adenosine monophosphate ;cAMP ; augmented cyclic guanosine monophosphate ;cgMP
RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia
report ; ischemic-hypertensive cardiomiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor 1 ; s1PR1 ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors
e-septal correlated ; PCWP ; e/e'lateral ; e/e'mean
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone
Nordic walking ; standard cardiac rehabilitation ; outcomes
cPG-recommended pharmacological treatment ; device consideration ; self-care education
gLS ; LVEF ; sa in predicting adverse CV events ; prognostic benefit ; conventional clinical ; echocardiographic systolic parameters
ERC induced recovery ; DAPC protein levels ; sarcomeric microstructure ; markers of SkM growth/differentiation ; myofibre regeneration
signalling cascades ; microRNAs ; bHLH transcription factor Hand2 ; postnatal mammalian myocardium ; embryonic gene programs in heart failure
Rad Q66p limits ; inhibitory actions ; Rad on cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ; LCX model ; LAD model 4 wk ; stenting ; left ventricle ; LCX ; LAD models
EH ; LV compliance ; lv end-diastolic volume ; idealized LV end-diastolic pressure ; hg β coefficient
mVA ; surgical ring implantation ; leaflet motion ; edge-to-edge anastomosis
HART enrolled 902 patients ; New York Heart Association ;NYHA ; class II ; hospitalized ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; E/E ; systolic dysfunction
BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF pathogenesis ; HF
English-language trials ; blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
Grading of recommendations assessment ; development and evaluation ;GRADe
three-year HF hospitalization
right heart circulatory failure ; conjoint education
ca(2+) influx ; l-type voltage-gated ca(2+) channels ; plateau phase of ventricular action potentials ; excitation-contraction ;EC ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; preserved ejection fraction
aldosterone antagonism ; heart failure aldosterone ; neurohormone ; electrolytes
bNP ; glomerular filtration rate ; hypertension ; transmitral E-wave/early diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ; RAS axis ; natural vasodilatory ; diuretic peptides
β-blockade ; cAMP-dependent protein kinase ; pKA ; downstream of β-adrenergic receptor activation
erythropoiesis-stimulating agent therapy
black race ; mortality/hospitalization ;hazard ratio ; cardiovascular mortality/HF hospitalization
percutaneous one-vessel model ; chronic myocardial ischemia ; stent coated ; polytetrafluoroethylene tube ; bottleneck shape
CHF predictive model ; curve ; genetic ;AUC ; clinical
logistic analysis ; AT ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index score
heart failure ;HF ; elevations ; tumor necrosis factor ;TNFα ; tNF antagonists ; HF
centers for Medicare and Medicaid Services ; cMS ; operationalized hospital quality of care outcomes ; publicly reported 30-day risk-standardized mortality ; readmission rates ; penalties
cox proportional hazard models ; time-dependent covariates ; follow-up ; familiar physician ; primary outcome of death ; urgent all-cause readmission
logistic regression analysis ; severe CAD ; diameter stenosis ; 3-vessel CAD ; 2-vessel CAD ; proximal left anterior descending artery
signal transduction cascade ; transcription factors ; pathological changes ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
hypertensive HFPEF ; sodium-restricted DASH diet ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular dilatation
aldactone Evaluation study ; symptomatic chronic advanced heart failure patients ; aldosterone antagonist ; spironolactone ; mortality
incidence and mortality outcomes of heart failure ; acute myocardial infarction
CHF after HCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ;nonadherence
pathophysiological origin
lVAD surgery ; normal albumin levels
creatinine ;hazard ratio
risk of death ; glomerular filtration rate
scientific literature ; clinical studies ; HM II ; economic evaluations ;HM II
low-dose dopamine ; low-dose nesiritide ; decongestion ; renal function
randomized trials ; HR variability/turbulence ; risk stratification of cardiac patients
complications after implantation ; lVAD therapy ; transplantation eligibility status ; device ; bTT ; DT
clinical ; radial artery tonometry variables
fully magnetically levitated centrifugal-flow chronic LVAS
eRK1/2 signalling ; signalosome complex ; scaffold protein drives ; kinases ; sequential phosphorylation ; effector molecules
breast cancer patients ; full Medicare coverage ; stage I-III breast cancer ; chemotherapy
ejection fraction ; b-type natriuretic peptide levels ; heart failure ; inhospital outcomes
diseased cardiomyocytes ; pDE2 activity ; cGMP synthesis ; nitric oxide donors ; pDE2 inhibition ; β-AR responsiveness
l-dKO mice ; cardiac IRS1 ; IRS2 proteins ; heart failure ; impaired cardiac energy metabolism ; p38α mitogen-activated protein kinase
ECs ; HDL ; phosphorylation ; eNOS-Ser(1177 ; eNOS-Thr ; PKc-βII-Ser ; p70s6k-Ser
low PASp ; peak o2 per kilogram
sts ; HH ; HM
mouse ventricular myocytes ; sarcomere shortening ; peakca(2+) transient
administrative databases ; province of Alberta
heart failure ; myocardial collage
cRT ON assignment ; time to death ; first HF hospitalization ;hazard ratio
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor 1 ; s1PR1 reciprocal downregulation ; cardiac hypertrophic response ; heart failure
relative risk (RR ; heart failure ; bisphophonates ; crude RR
Medicare fee-for-service beneficiaries ; centers for Medicare ; Medicaid Services demonstration ; propensity-score
implementation strategies ; physician adherence ; guideline recommendations in heart failure
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; ultrastructural ; antitumor activity
KCCQ summary scores ; New York Heart Association class ; HFpEF ; HF ; EF
Rhythm control therapy ; af ; atrial structure ; function ; sinus rhythm ; delayed rhythm control
acute heart failure ; renal dysfunction ; low-dose dopamine ; low-dose nesiritide ; decongestion ; renal function
HF ; body composition ; skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography
enrollment periods ; heart failure treatment
aCP ; restrictive red blood cell transfusion strategy ;trigger hemoglobin threshold ; higher hemoglobin levels
hospitals ; quality of care ; heart failure ;HF
interatrial shunt ; haemodynamic outcomes ; heart failure
right ventricular-pulmonary arterial coupling ;pulmonary vascular resistance
left ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bTT ; transplant-ineligible patients ; destination therapy
Caloric restriction ; aerobic exercise training on Peak oxygen Consumption ; Quality of Life ; Obese Older Patients ; Heart Failure ; Preserved Ejection Fraction
carvedilol ; metoprolol on inappropriate implantable cardioverter-defibrillator therapy ; MADIT-CRT trial ;Multicenter Automatic Defibrillator Implantation ; Cardiac Resynchronization Therapy
oral glucocorticoids ; dose-related gradient of HF risk
ivabradine group ; ea ; TAC
carvedilol ; inappropriate therapy ; metoprolol
systemic adverse events evaluation
testosterone supplementation ; exercise rehabilitation
peak VO2 ; percent lean body mass ; thigh muscle ;intermuscular fat ratio
guidelines-Heart Failure ; HF patients ; borderline ;EF
economic analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness model ; cost-effectiveness analyses ; disease management programs in heart failure
HFPSI ; risk of death ; all-cause medical hospitalization ; HF clinic outpatients ; HF resources
cardiac insulin-restance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model ; pasp increase ; peak o2 per kilogram
pathophysiology ; heart failure ; preserved ejection fraction ;HFPEF ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; posteriorly displaced papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVF ; cardioverter-defibrillator
rGK ; rem ; Rem2 ; Rad ; Gem/Kir ; monomeric g proteins ; ventricular action potential duration ; EC coupling ; cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac ; HF ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-MIBG
Swedish web-system for enhancement and development of evidence-based care in Heart disease ; Recommended Therapies registry
LVEF ; clinical composite response ; reverse remodeling parameters ; time to death ; HF hospitalization
brain natriuretic peptide ;bNP levels ; high BNP group
coprimary end points ; cumulative urine volume ; decongestion end point
tAPse ;longitudinal RV fiber shortening ; PASP ;force generated ; in vivo RV length-force relationship ; disclosing prognosis
pde superfamily ; pde2 ; cgMP ; cAMP hydrolysis ; negative cross talk ; cgMP ; cAMP signaling
N-terminal proBNP ;NT-proBNP ; midregional proANP ;MR-proANP ; adiponectin ; CHF ; bMI ; FM
re-hospitalization ; admissions per patient
mitochondrial-targeted antioxidant ; protective peptides Szeto-Schiller ; SS20 ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac arrest ; cardiopulmonary resuscitation ;CPR ; posterior wall infarction
hyperkalemia ; mineralocorticoid receptor antagonists ; heart failure
erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
type 2 diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; long-acting insulin products
uPR ; scn5a ; human ventricular systolic HF tissue samples ; human induced pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
ambulatory patients ; heart failure ;HF ; reduced ejection fraction ;rEF ; renin-angiotensin system ; RAS ; β-blockers
cochrane Effective Practice ; organisation of Care taxonomy
coPD ; CHF ; cRF
heart failure ; left ventricular ejection fraction ; four-week aerobic training
implantable cardioverter-defibrillator deactivation ; clinical status ; end-of-life treatment preferences
heart failure ; poor myocardial function ; dilated poorly contracting ventricles
cardioverter-defibrillator deactivation preferences ; distressing implantable cardioverter-defibrillator shocks
global left ventricular longitudinal systolic strain ; gLS ; left ventricular mechanics ; adverse cardiovascular ;CV ; atrial fibrillation
mouse Rad Q65p ; murine equivalent ; human Rad Q66p ; l-type currents ; cav1.2 ; cav1.3 channels ; wild-type Rad
patient ; MI characteristics yielded hazard ratios ; early-onset HF
national Medicare ; older patients ; acute care hospital ; HF ; AMI ; pna
cardiovascular events ; baseline sST2 status ; baseline sST2 status ; high ; ng/mL
ctnt ; NT-probNP ; aRIC HF model ;AUCs ; continuous NRIs
early-onset ; late-onset HF ; HF ; EF ; HF ; prevention strategies
incubation of EC ; HDL ;NYHA-IIIb ; phosphorylation ; eNOS-Ser(1177 ; phosphorylation ; eNOS-Thr
carvedilol ; von Willebrand factor ; metoprolol
mouse heart failure ;HF ; hypertensive heart disease ;HHD ; pathophysiology ; therapeutic targets ; HHD
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein content ; SR ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
test-retest reliability ; timed up & go ;TUG test ; advanced chronic obstructive pulmonary disease ;coPD ; chronic heart failure ;CHF ; chronic renal failure ;CRF
feasibility ; 12-week program of exercise ; intramuscular testosterone supplementation
HF ; long-term mortality ; LVEF
gLS outperformed left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa
heart failure ;HF ; plasma B-type natriuretic peptide ;bNP ; reduced ; preserved ejection fraction ; HF studies
home telemonitoring ; implanted monitoring devices ; medical support ; office hours ; structured telephone support (STS ; human-to-human contact ;HH ; human-to-machine interface
cox regression analysis ; beta-blockers ; beta-blockers ; inappropriate therapy ; antitachycardia pacing ; aTP
ethically ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
patient preferences ; competing priorities ; guideline-recommended medications
cost ; rhythm-control ; rate-control
median age ; women ; median left ventricular ejection fraction
fit ; unfit ; cRF distribution
cRT group ; control group ; hazard ratio
HFPSI model ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart Association class ; diabetes status ; atrial fibrillation/flutter
Medicare Patient Safety Monitoring system ;MPSMS ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia
CD34+vegFR2+ cells ; functional capacity ; 10-cell decrease ; CD34+vegFR2+ cells ; peak VO2
practice-level variation ; guideline-recommended treatment ; outpatients ; heart failure ; reduced ejection fraction
crude 28-day case-fatality rate ; concurrent HF ; case-fatality rate
cohort ; anthracycline exposure ; stem cell source ; autologous
resting tension (Fpassive-sarcomere length relations ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix
reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance training ; augmented feedback ; exercise capacity ; muscle strength ; quality of life
hospital performance ; readmission metrics ; all-cause readmission ; aCR ; 3m potential Preventable Readmission ; pPR ; centers for Medicare ; Medicaid 30-day readmission ;CMS
congestive heart failure visits ; ED visits
exercise duration ; rehabilitation
Excessive secretion of arginine vasopressin ; aVP ; physiologic processes ; CHF inhibition of aVP ; vasopressin receptor antagonist therapy
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
medication ; physical therapy ; implantable defibrillators ; circulatory support ; transplantation
sodium-restricted dietary ; stop hypertension diet ;DASH/SRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
rapid right ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTQ-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase 3 expression
metoprolol ; carvedilol ; sympathetic activity
acute HF trials ; RELAX-aHF ; ASTRONAUT ; PRONTO
hospitalized HF ; international classification of Diseases ; Ninth Revision ; Clinical Modification codes 404.x1 ; 404.x3 ; principal discharge diagnosis
Pulmonary capillary wedge pressure ; right atrial pressure ; pulmonary arterial
Rad Q65P ; gating movement ; channels ; wild-type Rad ; Q65P
heart failure ; global proteomics
aortic insufficiency ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; HF
discharge
life expectancy
heart failure discharges ; university of Connecticut health center
report ; New York Heart association ;NYHA ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPHASIS-HF study
echocardiograms ; left ventricular base ; midpapillary ; apex ; baseline ; IVC occlusion ; biVP ; twist ; apical ; basal rotations ; RS
direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF induced ; mice ; phenylephrine ; haemodynamic stress ; surgical method of transverse aortic constriction ;TAC
Muscle aerobic capacity ; rate constant ; postexercise phosphocreatine resynthesis ; Fontan adults
i-MIBG cardiac washout ; carvedilol ; metoprolol treatment ; β2-adrenergic receptor haplotype
acute myocardial infarction ; AMI ; incidence of and deaths attributable ; heart failure ;HF
h-dKO mice ; ventricular mass ; cardiac apoptosis ; fibrosis ; failure ; Akt ;forkhead box ; o-1 signaling ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCX ; proximal LCX ; mid LAD
postmarketing trials ; risk ; hospitalized heart failure ;hHF ; dipeptidyl peptidase-4 ; dPP-4 ; antihyperglycemic agents
quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity Index ;HFPSI ; University of Michigan HF clinic ;UM cohort
pde2 overexpression ; healthy cardiomyocytes ; cAMP levels ; l-type ca2 ; current amplitude ; inotropic effect ; acute β-AR stimulation ; basal contractility
inappropriate ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ;CRT ; dialysis-dependent patients ; heart failure ;HF
cardiorespiratory fitness ;CRF ; body mass index ; heart failure ; HF mortality
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF study ; eplerenone in Mild Patients Hospitalization ; SurvIval Study in Heart Failure
cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHF ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; p38 ; cardiac dysfunction ; insulin resistance ; type 2 diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; interventricular delay ;VVd ; regional circumferential strain ; radial strain
New York Heart Association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
non-LBBB ; QRS ; hazard ratio
abnormal ca(2+) handling ; dyssynchronous HF ; myofiber shortening velocity ; septum ; myofiber shortening ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure ; signaling pathway
CHF-derived c-Kit+ cells ; upregulated transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers
pKA subunits ; regulatory ;RIIα ; catalytic ;Cα ; phosphorylation ; HF
hFrEF ; left ventricular ejection fraction ; HFpEF ; left ventricular ejection fraction ; RAS- ; β-blocker ; index HF
g-protein-coupled receptors ; physiological ; reciprocal regulation ; mouse hearts ; chronic β-adrenergic receptor stimulation ; postischemic heart failure
concentric remodeling ; concentric hypertrophy ;CH ; left ventricular ;LV ; heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
body ; diet group ; exercise group
risk of event ; RV dysfunction ;hazard ratio
resting HR
tGF-β inhibition ; c-Kit+ cell phenotype ; function in vitro ; cardiac progenitor function ; cell expansion protocols
NT-probNP ; inflammatory biomarkers ; hsCRp ; IL6
BETs ; neurohormonally induced heart disease ; nanomolar doses ; JQ1 ; phenylephrine-mediated hypertrophy of cardiomyocytes ; pathological gene induction
BAT ; exercise capacity ; N-terminal pro-brain natriuretic peptide ; burden of heart failure hospitalizations ; GDMT-treated NYHA
p70s6K ; PKc-βII ; HDL ;NYHA-IIIb ; malondialdehyde bound ; HDL ;NYHA-IIIb
MLHF total score ; exercise ; exercise
nonpace ; non-DNx ; sham-Innervated ; sham-inv ; nonpace DNx ;sham-DNx ; pace non-DNx ;CHf-INv ; pace DNx ;CHf-DNx
HABC Battery score ; HF risk ; health ABC HF model ; SD ; risk ; competing risk
age ; sex ; ejection fraction ; frail ; biological phenotype ; risk of death
hemoglobin ;Hgb ; HRQoL ; training-induced changes ; HRQoL ; patients in Heart Failure ; HF-ACTION
atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; rhythm ; rate-control treatment strategies
heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation pulmonary embolism ; renal dysfunction
calcineurin/Nfat signalling ; miR-25 expression ; basic helix-loop-helix ;bHLH ; transcription factor dHAND ; diseased human ; mouse myocardium
exercise time ; PSSS ; btes
NT-probNP cutoff point ; 4-year survival ; admission
prognostic power ; rapid R-R interval oscillations ; non-linear HR variability ; short-term fractal scaling exponent
diastolic ; filling formalism ; relaxation/viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; spontaneous ventricular tachycardia ;HFVT ; HF ; VT ;HFVT ; structurally normal hearts
gLS ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF
VAD group ; ventricular assist device support ; ECMO group ; extracorporeal membrane oxygenation membrane support ; ECMO ; VAD
risk factors ; ischemic events ; is ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ;CRT-D
cost-effectiveness ; heart failure disease management programs ; evidence-based treatments
human resistin ; heart failure ; humanized mouse model lacking murine resistin ; transgenic ; human Retn gene ;Hum-Retn mice ; basal ; inflammation-stimulated resistin levels
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers
tgtttMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction
resynchronization-Defibrillation for Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT
heart failure patients ; confirmatory factor analysis ;CFA ; SCHFI ;Self-Care Maintenance ; Self-Care Management ; Self-Care Confidence
functional status ; wt ; NYHA class ; HFpEF ; HFrEF ; adherence ; prescribed therapy ; HFpEF ; death ; HF hospitalization
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-ERk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling
CHF ; SD testosterone levels ; testosterone ; placebo groups
functional MS ; LV dilatation ; heart failure ;HF ; LV size ; functional MS ; HF ; prolapse of degenerative mitral valve
New York Heart association class ; kccQ overall Summary ; Total Symptom domains ; Spearman correlations ; 2-way aNOVA ; HF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers
c57BL ; ang II infusion ; uninephrectomy ; ang II infusion ; salt loading ; ang II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; doppler early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; decompensated systolic heart failure ;HF
LV ejection fraction ; LV strain/strain rate ; systole ; diastolic indices ; LV strain rate ; diastole ; early transmitral flow
peak VO2 ; exercise ; body mass
age- ; sex-adjusted risk ; early-onset HF
AMI patient ; hospital
Mass spectrometry ; N- ; c-terminally processed forms ; circulating NT-proBNP ; physiological proteolysis ; pro2-Leu3 ; leu3-Gly4 ; pro6-Gly7 ; pro75-Arg76
sex-specific model ; ctnT ; NT-probNP ; laboratory report
HFpEF patients ; New York Heart Association class II ; III ; mean ejection fraction
depressed left ventricular ;LV ; systolic pressure ; pressure development ; ejection fraction ; fractional shortening ; cardiac output
baroreflex Activation Therapy ; Heart Failure ; Reduced Ejection Fraction
enrollment period
HF risk factors ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ; rheumatic fever ; Chagas' disease
adjusted hazard ratios ; high ; moderate ; low CRF categories
kccq ; HFpEF ; HFpEF ;log rank ; EF
baseline eGFR group ; eGFR group ; uncontrolled hypertension ; need of diuretics
myocardial phosphodiesterase-2 ; pDE2 ; heart failure ;HF ; pDE2-mediated effects on beta-adrenergic receptor ;β-AR ; cardiomyocytes
cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; inappropriate ATP ; shock therapy
epicatechin-rich cocoa ; Skm mitochondrial structure ; taub ; Ramirez-Sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; Maisel
follow-up visits ; risk of death ; urgent readmission
Mena overexpression ; TTA/tgttttMena mice ; TAC surgery ; cardiac hypertrophy ; TTA/tgttttMena
echocardiography ; reduction ; LV end-diastolic volume ; disappearance of MR ; mitral valve opening ; mVA ; pressure gradient
institution of PD ; diuretic refractory severe-end-stage HF
ATP production rates ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
high-risk subgroups ; eplerenone ; potassium ; potassium
patient aged ; New York Heart Association class III heart failure ; HF ; left ventricular ejection fraction ; p
bottleneck stent ; proximal LAD ; LCX ; reversible myocardial ischemia ;open stent ; ischemic heart failure ;occluded stent
potassium ; spironolactone ; non-AAs
obese participants ; body mass index ; chronic, stable HFPEF
proangiogenic effects ; B act via activation of VEGF pathway ; adenoviral vector ; decoy VEGF receptor ; ad-Flk ; control adenovirus ; ad-C
post-LVAD AI ; aortic valve oversewing ; leaflet repair ; bioprosthetic aortic valve replacement
exercise-induced pulmonary artery systolic pressure ;PASP ; stress Doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
literature ; MEDline ; EMBASE ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institut ; reviews and Dissemination ; evidence based practice Centres
joint-methods study ; veterans aged 50 years ; VA health care systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor block
heart failure ; blockade ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS synchrony ; CS ; STE ; surrogates ; CO
tAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ; pasp ; cox regression ; Kaplan-Meier
symptom limited maximal CPET ; CHF ; control ; exercise ; exercise
human heart failure ; mRNA splicing ; voltage-gated cardiac na+ channel α-subunit ; sCN5A ; truncated channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; new onset heart failure cellular responses to heart failure ; anthracycline ; childhood malignant disease treatment strategies
economic analysis ; Patient Management Interventions in Heart Failure Cost-Effectiveness model ; web-based simulation tool ; demographic ; clinical ; laboratory ; evidence-based medications
natriuretic peptides ;NPs ; b-type NP ; N-terminal pro-B-type NP ; acute heart failure ; Emergency Department ; acute dyspnea
peak oxygen consumption ; peak VO2 ; ven/vco2 slope ; exercise oscillatory ventilation ; eOV ; partial pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
eu ; bisphosphonates ; raloxifene ; general population
hypertension ; LV dilatation ; LV dysfunction ; mild MR ; MS
tolvaptan ; severe hyponatremia ; congestive heart failure patients ; standard diuretic therapy ; serum sodium levels
global longitudinal strain of left ventricle ; echocardiographic measurements ; baseline echocardiography ; cRT ; follow-up echocardiograms
platelet-activating factor ;PAF ; metabolic enzymes ; newly diagnosed heart failure
acute care surgery ;ACS ; oHT ; recipients bridged to transplantation ; medical therapy ; intravenous inotropes ; ventricular assist devices
HFpEF ; ivabradine ; exercise capacity ; left ventricular filling pressure response ; exercise ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;RAAS ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade
admission ; lVET ; unfavorable outcome
correction ; heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
adjusted median rate ratio ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy
congestive heart failure phenotypes ; mitochondrial damage induced ; TAC ; global attenuation ; mitochondrial proteome changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA level ; β-myosin heavy chain
HDL ; healthy controls ; CHF-NYHA-III ;HDL(NYHA-IIIb ; CHF-NYHA-II ; CHF-NYHA-II
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
standard error ; measurement value ; MDC ; 95% confidence level ; mDC95%
baseline ; heart failure T1-mapping values ; administration of contrast agent
HF ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol related
ST2 levels ; functional capacity ; clinical outcomes ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating Outcomes of exercise training ; HF-ACTION
cardiopulmonary exercise testing ; exercise rehabilitation ; chronic heart failure ;CHF
ischemic HF pathogenesis ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-ACTION ; exercise training ; HF ; low left ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kCCQ
cRT ; systolic dysfunction ; resynchronization reVErses Remodeling ; Systolic left vEntricular dysfunction ; reVERSe ; left ventricular ; ejection fraction ;LVEF
glomerular filtration rate ; eGFR ; eGFR ; age ; type 2 diabetes ; total cholesterol ; lDL-cholesterol ; CLCNKA GG genotype
echocardiography ; LV end-diastolic dimension ; LV end-diastolic pressure ;wall stress ; lung weight ; untreated ACF groups ; sham group
elateral ; diagnostic performance ; s'lateral ; aUC
spironolactone
rate-control patients ; cardiac procedures ; cost ; antiarrhythmic drugs
descriptive assessment ; diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone post myocardial infarction Heart failure Efficacy ; survival study ; post-myocardial infarction patients ; heart failure ; mortality ; hospitalizations ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; inappropriate implantable cardioverter-defibrillator therapy ; MADIT-CRT ;Multicenter Automatic Defibrillator Implantation ; Cardiac Resynchronization Therapy
risk reduction ; heart failure-related mortality
DASh/sRD reduced clinic ; 24-hour brachial systolic pressure ; central end-systolic pressure
HF ; obese ; body mass index ≥35 kg/m ; black ethnicity ; idiopathic-dilated cardiomyopathy
all-cause mortality ; hospitalization ; HF ; LVEF
idiopathic dilated cardiomyopathy ; negative coronary angiography
european society of cardiology guidelines ; HFPEF ; heart failure ; preserved LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ;impaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
signaling paradigms ; β1ARs ; s1PR1s ; myocyte ; cAMP production ; direct interaction ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
PAF-CPT ; PAF levels ; lyso-PAF-AT ; downregulated ; PAF-AH ; lp-PLA2
heart failure ;mean ejection fraction
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas
skeletal muscle mass t-score ; young normal reference mean
exercise ; testosterone group ; baseline in peak oxygen uptake ; Beck depression inventory ; leg strength ; medical outcomes ; short-Form quality of life domains
RAS- ; β-blocker uptitrations ; composite end-point of all-cause mortality ; HF readmissions ; HFrEF ;hazard ratio
patients enrolled in Heart Failure ; controlled Trial Investigating Outcomes of exercise training ;HF-ACTION ; social support ; barriers to exercise score
ST2 ; death ; hospitalization ;hazard ratio ; cardiovascular death ; HF hospitalization ;hazard ratio
New York Heart association ; Fontan adults ; cardiopulmonary exercise testing ; lean mass quantification ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
low-dose dopamine ; low-dose nesiritide ; diuretic therapy ; renal function
randomized trial ; CRT ; New York Heart Association class III ; IV heart failure ; left ventricular ejection fraction ; QRS duration ; echocardiographic evidence of left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes
HF ; lyso-PAF-AT ; PAF-CPT ; PAF levels ; PAF-AH ; lp-PLA2
medical therapy ; redo sternotomy ; aortic valve procedures ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve procedure ; open surgery ; aortic valve replacement
cutoff value ; plasma N-terminal pro-B-type natriuretic peptide ;NT-proBNP ; acute heart failure ; admission ; emergency department
cardiac troponin T ;ctnT ; high-sensitivity assay ; N-terminal pro-B-type natriuretic peptide ;NT-probNP ; incident HF ; HF risk prediction ; Atherosclerosis Risk in Communities ;ARIC
body mass index ; event rate ;HR per kg/m
PARTICIPANTS ; median age ; 70y ; median body mass index ; 25.6kg/m ;interquartile range ; COPd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; HF hospitalizations ; dialysis patients
covariates ; EH ; LV contractility ; lower LVEF ; ratio of systolic blood pressure ; end-systolic volume
echocardiography ; moderately dilated LV ; end-diastolic volume index ; 84 mL/m2 ; LV ejection fraction ; mild MR ; mitral valve opening ; MS ; mVA ; pressure gradient ; 8.4 mm Hg
double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration rate
BETs ; chromatin-mediated signal transduction ; pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; naFAT ; nuclear factor-κb ;NF-κb ; transcription factor GATA4
mortality ; hospitalization ; exercise tolerance ; quality of life ; cardiovascular events ; myocardial infarction ; congestive heart failure exacerbation ; arrhythmia ; cardiac death
all-cause ; cardiovascular mortality
EO-CFUs ; diabetes ; 10-EO-CFU increase ; peak VO2
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; l-type ca2 ; myocardial tissues ; isolated cardiomyocytes ; experimental HF
east ; atrial fibrillation ; Stroke prevention Trial
exercise capacity ; peak oxygen consumption ;VO2 ; ml/kg/min ; QOL ; Minnesota Living with Heart Failure ;MLHF
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; treatment heart failure
low left ventricular ejection fraction ; patients ; HF ; preserved left ventricular ejection fraction ; hospital ; acute ; outpatient ; financial costs
HF patients ; HFrEF ; left ventricular ;LV ; ejection fraction ;HFpEF ; echo-Doppler studies ; N-terminal pro-brain-type natriuretic peptide assessment
low-volume EDs
cardiac transplant ; ECCT patients ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
HABC Battery scores ; health ABC HF risk model ; discrimination ; C-index ; HF ;net-reclassification-improvement ; HF
construct validity ; self-Care Maintenance Scale ; cFI ; RMSEA ; self-Care management Scale ; cFI ; RMSEA ; self-Care Confidence scale
BAT ; distance walked ; quality-of-life score
preoperative hypoalbuminemia ; postoperative normalization of albumin levels
length of stay ; 30-day rehospitalization ; acute myocardial infarction ;AMI
heart failure ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; left and right ventricular assist devices
SAF ; PF mean catheterization ; central venous pressure ; central venous pressure ; hg ; sVR index
admission median BNP levels ; reduced EF ; preserved EF
heart failure admission ; heart transplantation ;LV assist device ; death ;hazard ratio
LV ejection fraction ; velocity of circumferential shortening ; systolic elastance ; contractile efficiency ; aCF ; allopurinol rats ; o2 consumption rate ; isolated cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVH ; relative wall thickness ;RWT ; CR ; LVH ; RWT ; CH ;LVH ; RWT
angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension
blood pressure ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring 30
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic measures ; N-terminal pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory
interaction term analysis ; severely reduced LVEF ; risk ; long-term mortality
wstar-Kyoto ; lean ZSF1 ; obese ZSF1 ; high-fat diet ; euthanization
Kaplan-Meier curves ; log-rank testing ; risk stratification ; low-risk group ; UM/VA/VA-RT cohorts
cox regression analyses ; AF type ; long-standing persistent persistent AF ; lack of hypertension ; maintenance of sinus rhythm
chronic HF-REF ; NYHA functional class II ; eGFR ; potassium ; eplerenone
body composition ; FFM ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHF ; CC ; non-cachectic CHF ; myocardial infarction-both
baseline characteristics ; drug dose ; spironolactone ; end point of death ; hospitalization ; HF ;hazard ratio ; AAs
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump function ; pulmonary arterial hypertension ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; HF hospitalization
index ED visit ; low-volume ED cases ; 30-day death/all-cause readmission ; high-volume EDs
implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ;hazard ratio ; pulmonary vascular resistance
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association class I to III
end stage heart failure ; ABCd classification ; American College of Cardiology ; acc ;American Heart Association ; AHA ; New York Heart Association ;NYHA
mVA ; continuity equation ;LV end-diastolic volume ; LV end-systolic volume ; mitral filling flow volume ; velocity time integral ; mitral filling flow ; continuous wave Doppler echocardiography ; MR
statitistical ; RM trended ; all-cause mortality ; sts HH ; office hours ; t24/7
HFPSI ; Ann Arbor Veterans' Affairs HF clinic ;VA-RT cohort
non-AAs ; spironolactone dose ; hyperkalemia ; potassium
risk of long-term mortality ; LVEF ;hazard ratio
HFpEF ; HFpEF ; uha class III ; distance ; walk test (6-MWT ; adherence ; medications
pulmonary arterial systolic pressure ; right ventricular ; tricuspid annular plane systolic excursion ;TAPSE ; diastole ; end-systole
severe CAD ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes risk factors ; dyslipidemia ; hypertension
receiver operating characteristic curve ;AUC ; e/e ; ratios ; PCWP estimation ; e/elateral ; e/emean
trastuzumab-treated patients ; coronary artery disease ;HR ; hypertension
LVEF ; clinical composite response ; CRT ON ; CRT OFF ; LV end systolic volume index ; LV mass
tGF-β signaling ; tGF-β receptor type I ; smad 2/3 ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog
HFrEF ; diuretics ; co-morbidities
HF ; postoperative echocardiography ; normal sized LV ; end-diastolic volume index ; 71 mL/m2 ; LV ejection fraction ; MR ; preserved mitral valve opening ; mitral valve area ; pressure gradient
systolic heart failure ;ejection fraction ; placebo ; ivabradine ; SHIft ; systolic Heart Failure Treatment ; if inhibitor ivabradine Trial
figures ; tAPse/PASp ; tpse ; tpse ; tpse ; haard ratio ; tpse ; tpse
Chronic Kidney Disease Epidemiology collaboration equation ; glomerular filtration rate ; eGFR
paraDIGm-HF ; stabilized chronic heart failure ; systolic dysfunction ;LV EF ; functional class NYHA II-III ; bNP/NT-pro BNP ; primary endpoint ;cardiovascular death ; hospitalization for heart failure
reverse remodeling ; pre-CRT LV end-diastolic dimension index ; global longitudinal strain ; left ventricle ; left atrial area ; right ventricular end-diastolic area index ; right atrial area ; right ventricular fractional area change
hyperkalemia ; African Americans ;AAs ; non-AAs ; New York Heart Association ;NYHA ; IV HF ; left ventricular dysfunction ; spironolactone
iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS2 ; iRS1 ; iRS2 double-knockout ; l-dKO
natriuretic peptide ; N-terminal pro-B-type natriuretic peptide ; stable coronary artery disease B-type natriuretic peptide ; natriuretic peptide ; N-terminal fragment ;NT-proBNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers ; interquartile range
ivabradine ; exertional ; peak early diastolic mitral flow velocity ; peak early diastolic mitral annular velocity
liberal transfusion protocols ; short-term mortality rates ; aggressive protocols ; relative risk among trials ; acute coronary syndrome
risk of death ; unplanned readmission
hek ; human embryonic kidney ; β1AR ; s1PR1 downregulation ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; β-adrenergic receptor agonist
natriuretic peptide ; flow-mediated dilatation
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke
in conjunction ; diastolic function
disease risk score ; dRS-stratified analyses ; saxagliptin ; sitagliptin ; pioglitazone
revascularization ;coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure
biomedical treatment ; CHm ; left ventricular ejection fraction
open-label crossover study ; stable heart failure patients ; left ventricular ejection fraction ; arg16/Gln27 ; gly16/Glu27 haplotype ; β2-receptor ; carvedilol ; metoprolol
low-volume ED cases ; death/hospitalization/ED visit
health Buddy program ; risk-adjusted all-cause mortality ;hazard ratio (HR ; confidence interval ;CI ; matched controls
multivariable-adjusted hazard ratios ;
ctnt ; NT-probNP ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; body mass index ; prevalent coronary heart disease ; heart rate
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ; HF-ref ; New York Heart Association ;NYHA ; glomerular filtration rate ; eGFR ; serum potassium
low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; 8574 mL ; placebo ; 8296 mL ; cystatin C level
standard care ; Nordic walking led ; functional capacity ; self-reported physical activity
high risk of hyperkalemia ; wRF ; diabetes ; eGFR ; systolic blood pressure ; HF ; cardiovascular mortality
PAF ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dTT ; choline ; 1-alkyl-2-acetyl-sn-glycetyl-sn-sn-glycerol cholinephosphotransferase ;PAF-CPT ; catabolic isoenzymes ;PAF-acetylhydrolase ; lipoprotein-associated phospholipase A2 ; lp-PLA2 ; leukocytes
ivabradine group ; baseline ; follow-up exercise capacity ; peak oxygen uptake ; peak early diastolic mitral flow velocity
CHF ; odds Ratio ; pre-HCT chest radiation ; NAD(p)h-oxidase subunit RAC2 ;
baseline ; NYHA classification ; class III ; class II ; class III ; class I
low-dose dopamine ; 72-hour cumulative urine volume
haard ratio ; baseline glomerular filtration rate ; 15-mL/min decrease ; chronic obstructive pulmonary ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction
Kansas City Cardiomyopathy Questionnaire ;
